

INDEX

Volume Twenty-Nine—January through December 1995

The Annals of Pharmacotherapy

JANUARY Pages 1-112
FEBRUARY Pages 113-220
MARCH Pages 221-336
APRIL Pages 337-452

MAY Pages 453-556
JUNE Pages 557-654
JULY/AUGUST Pages 655-830
SEPTEMBER Pages 831-960

OCTOBER Pages 961-1072
NOVEMBER Pages 1073-1170
DECEMBER Pages 1171-1332

SUBJECT INDEX

A-B

AIDS, see **Acquired immunodeficiency syndrome**
Acetofenac, leukocytoclastic vasculitis, hemoptysis (L) 1168
Acetazolamide, pseudotumor cerebri (L) 318
Acquired immunodeficiency syndrome, attitudes, knowledge, Arizona pharmacists (RR) 1218; diagnosis, reporting, expanded surveillance definition (NC) 110; incidence, 1994 (NC) 333; microsporidial keratoconjunctivitis, topical fumagillin (CR) 872; pancreatitis, paromomycin-induced (CR) 22; rationing high-cost drugs (O) 78; recent advances (A) 1038; toxoplasmosis (A) 760; women (NC) 451; zidovudine, anemia, recombinant erythropoietin (A) 778
Adenosine, acute theophylline intoxication (A) 1285; supraventricular tachycardia, pregnancy (L) 938
Adrenoleukodystrophy, Lorenzo's oil (A) 312
Allergies, hypersensitivity, piperacillin/tazobactam (L) 936; tobramycin (CR) 704
Alprazolam, tinnitus (A) 311
Alzheimer's disease, nicotine, transdermal (A) 314
Ambulatory care, recent advances, diabetes mellitus (A) 716; pharmacy practice (A) 716
American Pharmaceutical Association, Code of Ethics for Pharmacists approved (NC) 111; conference proceedings (NC) 218
Aminoglycosides, pharmacokinetic variability (L) 939
Amiodarone, atrial fibrillation (A) 596; oral, fatal hepatotoxicity (CR) 582; toxicity (A) 599
Amphotericin B, in dextrose, rapid infusion (A) 523; lipid emulsion vs. conventional administration (RR) 1197; prophylaxis, bone marrow transplant (A) 921; toxicity, administration in fat emulsion (CR) 496; dosage regimens (RR) 1081
Amyotrophic lateral sclerosis, gabapentin (O) 1164; gabapentin, lamotrigine (A) 1160
An Opinion, see also **Editorials**; Poirier, Therese I, Giannetti, Vincent J, Clinical and Ethical Perspectives on Rationing of High-Cost Drugs, 78; Welty, Devin F, Schielke, Gerald P, Rothstein, Jeffrey D, Potential Treatment of Amyotrophic Lateral Sclerosis with Gabapentin: A Hypothesis, 1164
Analgesia, local, opioids (A) 189
Analgesics, prescribing, South Africa (L) 1302
Anaphylaxis, cisplatin (CR) 260
Anemia, autoimmune hemolytic, diclofenac (L) 787; prematurity, erythropoietin (A) 167
Antibiotics, beta-lactam, continuous infusion (A) 415; pharmacodynamics (A) 415; pharmacokinetics (A) 418; dosage adjustment, kidney failure (RR) 1202; step-down therapy, pharmacoeconomic benefit (RR) 561
Antidepressants, tricyclic, diabetic peripheral neuropathy (A) 772; use in Sweden (RR) 566; venlafaxine, review (A) 387
Antihypertensives, related to falls, elderly (RR) 354
Antiinflammatory drugs, nonsteroidal, asthma (L) 199, interaction, warfarin (A) 1274, (E) 1289, postmarketing surveillance network (RR) 1208; topical, soft tissue injury (A) 780; steroidal, hyperlipidemia, solid organ transplant (A) 881
Antineoplastic agents, adverse reactions (A) 294; cost (A) 295
Antioxidants, glutathione (A) 1266
Antithrombotic agents, pharmacology (A) 892
Anxiolytics, clinical trial flaws, Japan (L) 432
Apomorphine, Parkinson's disease (A) 282; pharmacokinetics (A) 282
Arab Americans, diabetes, metabolic risk factors (RR) 573
Arginine, review (A) 175
Arizona, pharmacists' attitudes, knowledge, HIV and AIDS (RR) 1218

Armstrong, Deborah K, member, Council of the Society of Critical Care Medicine (NC) 960
Arrhythmic, intravenous vasopressors (A) 269
Arthritis, prevalence, women (NC) 810; rheumatoid, minocycline (A) 186
Ascorbic acid, plasma lipid concentrations (A) 1129
Aspergillosis, short-term steroid therapy (CR) 1235
Aspirin, interaction, warfarin (A) 1276
Asthma, emergency department use, health maintenance organization (RR) 251; exercise-induced, clenbuterol (A) 75; heparin inhalation (A) 71; incidence (NC) 219; management program, emergency department visits (RR) 5; mild, chronic, corticosteroids (L) 1170; nonsteroidal antiinflammatory drugs (L) 199
Atenolol, compared with bisoprolol, essential hypertension (A) 408
Atherosclerosis, dietary flavonoids (A) 627
Athletes, exercise-induced asthma, clenbuterol (A) 75
Atovaquone, toxoplasmosis (A) 765
Atrial fibrillation, amiodarone (A) 596
Autism, treatment (A) 47
Azelastine, inhibition, platelet activating factor, eosinophils (L) 318
Azithromycin, cryptosporidial diarrhea (CR) 991; interaction, food (A) 913; toxoplasmosis (A) 764
Benzodiazepines, interaction, erythromycin (A) 909; related to falls, elderly (RR) 354
Benzyl alcohol, toxicity, with diazepam infusion (L) 632
Beta agonists, see **Sympathomimetics**
Beta-blocking agents, see **Sympatholytics**
Bile acid sequestrants, hyperlipidemia, solid organ transplant (A) 885
Bisoprolol, adverse reactions (A) 411; compared with atenolol, essential hypertension (A) 408; compared with nifedipine, essential hypertension (A) 410; compared with nitrendipine, essential hypertension (A) 410; compared with verapamil, angina (A) 411; cost (A) 412; dosage (A) 411; pharmacokinetics (A) 407; pharmacology (A) 404; review (A) 403
Bismycin, with cisplatin, etoposide, angina pectoris (CR) 138
Board of Pharmaceutical Specialties, certification examination (NC) 1188; Pharmacotherapy Specialty Certification Examination changes (NC) 111; policy/procedure review (NC) 811
Book reviews, Activated Charcoal in Medical Applications (DO Cooney), 1176; Anesthetic Toxicity (SA Rice, KJ Fish), 793; Basic Clinical Pharmacokinetics, 3rd Edition (ME Winter), 944; Benzodiazepine Dependence (C Hallstrom), 203; Biotechnology and Safety Assessment (JA Thomas, LA Myers), 435; Carcinogenesis: Target Organ Toxicology Series (MP Waalkes, JM Ward), 635; Cardiovascular Disease Risk Factors: New Areas for Research (WHO Technical Report Series No. 841), 1175; Cardiovascular Pharmacology and Therapeutics (BN Singh, VJ Dzau, PM Vanhoutte, RL Wootley), 1053; Chemotherapy Handbook, 86; Clinical Handbook of Psychotropic Drugs, 4th Revised Edition, (KZ Bezchlibnyk-Butler, JJ Jeffries, BA Martin), 86; Clinical Paths: Tools for Outcomes Management (PL Speth), 1174; Clinical Pharmacology: An Electronic Drug Reference and Teaching Guide (S Reents, J Seymour), 202; Developmental Toxicology (CA Kimmel, J Buelke-Sam), 1055; Discovering New Medicines: Careers in Pharmaceutical Research and Development (PD Stonier), 1306; Drugs and the Lung (CP Page, WJ Metzger), 945; Drugs in Pregnancy and Lactation, 4th Edition (GG Briggs, RK Freeman, SJ Yaffe), 1053; Essentials of Critical Care Pharmacology, 2nd Edition (B Chernow), 944; Ethical Responsibility in Pharmacy Practice (RA Buerki, LD Vottero), 1176; Experimental Therapeutics in Addiction Medicine (S Magura, A Rosenblum, B Stimmler), 1305; Home Health Care Practice, 2nd Edition (PN Catania, MM Rosner), 541; Implementation of the Global Strategy for Health for All by the

Year 2000: Second Evaluation; Eighth Report on the World Health Situation, Volume I—Global Review (AI Wertheimer), 202; Laboratory Test Handbook, 3rd Edition with Key Word Index (DS Jacobs, WR DeMott, PR Finley, RT Horvat, BL Kasten, LL Tiltzer), 88; Manual of Antibiotics and Infectious Diseases, 8th Edition (JE Conte Jr), 1174; Neurobehavioral Toxicity: Analysis and Interpretation (B Weiss, JL O'Donoghue), 635; Notes on Medical Bacteriology, 4th Edition (JD Sleight, MC Timbury), 1176; Nursing94 Drug Handbook (S Loeb), 436; Pharmacology and Therapeutics in Respiratory Care (TJ Witek Jr, EN Schacter), 791; Pharmacology of the Contraceptive Steroids (JW Goldzieher, K Fotherby), 203; Physical Pharmacy, 4th Edition (A Martin), 1307; Pocket Book of Critical Care Pharmacotherapy (B Chernow), 944; Principles and Methods of Toxicology, 3rd Edition (AW Hayes), 542; Principles of Clinical Toxicology, 3rd Edition (TA Gossel, JD Bricker), 541; Principles of Drug Information and Scientific Literature Evaluation (FJ Ascione, CC Manfredi, MA Parenti), 320; Psychopharmacology: The Fourth Generation of Progress (FE Bloom, DJ Kupfer), 1054; Psychosocial Aspects of Sickle Cell Disease: Past, Present, and Future Directions of Research (KB Nash), 1306; Quality Assurance for Biopharmaceuticals (JF Hussell), 321; Refractory Depression: Current Strategies and Future Directions (WA Nolen, J Zohar, SP Roone, JD Amsterdam), 791; Rehabilitation After Cardiovascular Diseases, with Special Emphasis on Developing Countries—Report of a WHO Expert Committee (WHO Technical Report Series 831), 946; Reproductive Toxicology, 2nd Edition (Target Organ Toxicology Series) (RJ Witschek), 1056; Searching for Magic Bullets: Orphan Drugs, Consumer Activism, and Pharmaceutical Development (LR Vasara, Michael Montagne), 793; Social Pharmacy: Innovation and Development (G Harding S Nettleton, K Taylor), 1055; TDM: Therapeutic Drug Monitoring (GE Schumacher), 1305; The ABCs of Antihypertensive Therapy (FH Messeri), 434; The Anticancer Drugs, 2nd Edition (MP Gosland, BL Lum), 320; The Coming Phase: Newly Emerging Diseases in a World Out of Balance (L Garrett), 792; The Fibromyalgia Syndrome: Current Research and Future Directions in Epidemiology, Pathogenesis, and Treatment (SR Pillemer), 1177; The Health Care Organizational Survey System (DN Lombardi), 945; The International Pharmacopoeia, 3rd Edition, Volume 4 (R Bilger, UV Banakar), 946; The Pharmaceutical Code: Principles and Practice of Pharmacology, 12th Edition (W Lund), 435; Tropical Disease Research: Progress 1991—92/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases, 321; Tuberculosis: Pathogenesis, Protection, and Control (BR Bloom), 1054

Bumetanide, adverse reactions, review (A) 1012; continuous infusion, chronic kidney failure (A) 1012
Bupropion, eosinophilia (CR) 867
Bupropion, autism (A) 51

C

Calcium antagonists, extrapyramidal symptoms (A) 73; premature labor (A) 520; prophylaxis, radiocontrast nephrotoxicity (A) 187
Cambridge Cognitive Examination, psychometric testing, elderly (RR) 982
Canada, pediatric drug monographs (L) 1052
Cancer, breast, node-negative, pepsinogen C expression (L) 940; tamoxifen (A) 293; therapy (A) 289; prognosis (A) 290; morphine infusion, pump evaluation (RR) 972

Candida albicans, resistance (A) 1037

Candidiasis, oropharyngeal, esophageal, ketoconazole, fluconazole salivary concentrations (RR) 10

Cappelletti, Diane, assistant professor, Department of Pharmacy Practice, Wayne State University (NC) 1321

Capsaicin, diabetic peripheral neuropathy (A) 773

Captopril, interaction, chlorpromazine (A) 606

Carbamazepine, autism (A) 51; diabetic peripheral neuropathy (A) 774; interaction, clarithromycin (A) 909, erythromycin (A) 907, josamycin (A) 912, miocamycin (A) 913; lymphopenia (CR) 865; pharmacokinetics, obese, lean subjects (RR) 843; Stevens-Johnson syndrome (L) 538

Cardiology, congestive heart failure, bioelectrical impedance analysis (RR) 1091; thrombosis, review (A) 892; vasopressors, proarrhythmic effects (A) 269

Cardoni, Alex A., research grants (NC) 1188

Carter, Barry L., Award for Achievement for Sustained Contributions to the Literature of Pharmacy in Health Systems, American Society of Health-System Pharmacists (NC) 1070; professor, chairman, Department of Pharmacy, University of Colorado College of Pharmacy (NC) 336

Cefadroxil, liver disorder (CR) 875

Cefazolin, prophylaxis, gastric restrictive surgery (L) 935

Cefepodoxime proxetil, oral, pharmacoeconomic benefit, step-down from intravenous ceftriaxone (RR) 561

Ceftazidime, compared with piperacillin/tazobactam (A) 509

Ceftriaxone, intravenous, step-down to oral cefepodoxime proxetil, pharmacoeconomic benefit (RR) 561

Charcoal, activated, adverse reactions (L) 84

Chemistry, fluvastatin (A) 744; lovastatin (A) 744; pravastatin (A) 744; progesterins (A) 736; quinupristin/dalfopristin (A) 1022; simvastatin (A) 744; sulpiride (A) 152

Chloralhydrate, interaction, nicotine (A) 1142

Chlorpromazine, compared with sulpiride, schizophrenia (A) 156; interaction, captopril (A) 606, guanethidine (A) 607, methylglucoside (A) 606, propranolol (A) 605

Cholestyramine, acidosis, hyperkalemia (L) 199

Chrichilles, Elizabeth A., study grant awarded (NC) 552

Cilastatin, with imipenem, compared with piperacillin/tazobactam (A) 507

Cimetidine, no interaction, cyclosporine (RR) 1088

Cinnarizine, extrapyramidal symptoms (A) 73

Ciprofloxacin, Henoch-Schönlein purpura (L) 84; hepatotoxicity (CR) 257; hypertension, infant (L) 1049; *Pseudomonas aeruginosa* (CR) 1122

Cisapride, chronic idiopathic constipation (A) 1161; stability, liquid dosage form (RR) 125

Cisplatin, anaphylaxis (CR) 260; neurologic toxicity (CR) 134; with etoposide, bleomycin, angina pectoris (CR) 138

Clarithromycin, delirium (CR) 486; interaction, carbamazepine (A) 909, didanosine (A) 910, digitalis (A) 910, rifabutin (A) 910, (A) 1152, terfenadine (A) 909, theophylline (A) 909, zidovudine (A) 910; with pyrimethamine, toxoplasmosis (A) 765

Clearance, see **Elimination**

Clenbuterol, athletic performance, exercise-induced asthma (A) 75

Clinidamycin, parenteral, dosing regimens, meta-analysis (RR) 852; toxoplasmosis (A) 761; with pyrimethamine, toxoplasmosis (A) 763

Clinical studies, amiodarone, atrial fibrillation (A) 599; bisoprolol (A) 408; desogestrel (A) 738; erythropoietin (A) 168; fluvastatin (A) 745; gestodene (A) 738; granisetron (A) 1242; Japan, flaws (L) 432; lamotrigine (A) 146; lovastatin (A) 745; media sensationalism (E) 629; norgestimate (A) 738; omeprazole (A) 1255; piperacillin/tazobactam (A) 507; pravastatin (A) 745; rimantadine (A) 303; risperidone (A) 612; simvastatin (A) 745; sulpiride (A) 152; with sympathomimetics, premature labor (A) 516; torsemide (A) 397; venlafaxine (A) 389

Clomipramine, autism (A) 51

Clonidine, autism (A) 51; interaction, haloperidol (A) 605

Clozapine, interaction, enalapril (A) 606

Cocaine, determination, emergency department (L) 82

Colony-stimulating factors, use, cost (RR) 475

Compatibility, haloperidol/diphenhydramine (L) 1168; ondansetron hydrochloride/perphenazine hydrochloride (RR) 1106

Computers, adverse drug reactions, monitoring (L) 788; public-access bulletin board, drug information (RR) 1224

Concentrations, dobutamine, actual vs. ordered (RR) 1095; dopamine, actual vs. ordered (RR) 1095; epinephrine, actual vs. ordered (RR) 1095; lipid, ascorbic acid (A) 1129; phenytoin, Sheiner-Tozer method, hypoalbuminemia (RR) 667, dex-methasone interaction (L) 935, rebound after plasmapheresis (CR) 592, with valproic acid (RR) 470; salivary, fluconazole (RR) 10, ketoconazole (RR) 10, thiothixene (L) 789

Constipation, chronic idiopathic, cisapride (A) 1161

Contraceptives, oral, interaction, nicotine (A) 1144

Coronary disease, vitamin E (A) 531

Corrections, cyclosporine interactions, 789; missing acknowledgment, 1304

Corticosteroids, analog, diabetic peripheral neuropathy (A) 775

Crismon, M. Lynn, nominated for appointment, public advisory committee, FDA (NC) 336; Psychopharmacology Drugs FDA Advisory Committee (NC) 960

Critical care, acute respiratory distress syndrome, review (A) 1002; gentamicin pharmacokinetics, open fractures (RR) 117; haloperidol, continuous intravenous infusion (CR) 690; ketoconazole, prophylaxis, acute respiratory distress syndrome (A)

784; nitric oxide synthase inhibitors, septic shock (A) 36; pediatric, dopamine, dobutamine, epinephrine, actual vs. ordered concentrations (RR) 1095; rifampin-fluconazole interaction (CR) 994; thrombocytopenia, risk factors (RR) 835

Cryptosporidiosis, HIV-related, paromomycin-induced pancreatitis (CR) 22

Cryptosporidium parvum, azithromycin (CR) 991

Cyclophosphamide, antidiuresis, furosemide (A) 1012; hemorrhagic cystitis, mesna prophylaxis (A) 918

Cyclosporine, hyperlipidemia, solid organ transplant (A) 881; interaction, erythromycin (CR) 127, (A) 908, isoniazid (CR) 127, josamycin (A) 912, miocamycin (A) 913, rifampin (CR) 127, roxithromycin (A) 911; interactions (L) 789; no interaction, cimetidine (RR) 1088, famotidine (RR) 1088; pharmacokinetics, venovenous hemodiafiltration (CR) 374; with vitamin E, improved absorption (A) 67

Cyproterone, hepatotoxicity (L) 634

Cystic fibrosis, domate alfa, cost (RR) 459, (L) 1050; tobramycin, hypersensitivity (CR) 704

Cytochrome P450 enzymes, recent advances (A) 619

D

Dalfopristin, with quinupristin, adverse reactions, review (A) 1025, chemistry (A) 1022, pharmacodynamics (A) 1025, pharmacokinetics (A) 1024, resistance (A) 1024, review (A) 1022

Dapsone, with pyrimethamine, toxoplasmosis (A) 762

Dasta, Joseph F., nominated for appointment, public advisory committee, FDA (NC) 336; professor, College of Pharmacy, College of Medicine, Ohio State University (NC) 814

Delafente, Jeffrey C., nominated for appointment, public advisory committee, FDA (NC) 336

Dependence, zidovudine (L) 540

Dermatitis, exfoliative, omeprazole (L) 82

Desogestrel, adverse reactions (A) 738; pharmacokinetics (A) 737

Dexamethasone, interaction, phenytoin (L) 935

Dextroamphetamine, autism (A) 51

Diabetes mellitus, metabolic risk factors, Arab Americans (RR) 573; recent advances (A) 716

Diabetic neuropathy, peripheral, capsaicin (A) 773, carbamazepine (A) 774, corticotropin analog (A) 775, gamma-linolenic acid (A) 774, gangliosides (A) 774, glycemic control (A) 771, lidocaine (A) 774, mexiletine (A) 774, phenytoin (A) 774, review (A) 769, tolrestat (A) 772, tricyclic antidepressants (A) 772, uridine (A) 775

Diarrhea, *Pseudomonas aeruginosa*, ciprofloxacin (CR) 1122

Diuretics, infusion, benzyl alcohol toxicity (L) 632; interaction, nicotine (A) 1142

Diclofenac, autoimmune hemolytic anemia (L) 787; necrosis, fasciitis (CR) 264; thrombocytopenia, neutropenia (CR) 713

Didanosine, interaction, clarithromycin (A) 910

Diffusional, interaction, warfarin (A) 1276

Digitalis, interaction, clarithromycin (A) 910

Digoxin, interaction, erythromycin (A) 908; related to falls, elderly (RR) 354; serum fluorescence polarization immunoassay, itraconazole (L) 938

Diltiazem, erythema multiforme, increased hepatic enzymes (L) 317; extrapyramidal symptoms (A) 74

Diphenhydramine, compatibility, haloperidol (L) 1168

Diphtheria, epidemic (NC) 551

Dipyridamole, with thallium-201, interaction, pentoxifylline (A) 425

Dirithromycin, interaction, theophylline (A) 911

Disopyramide, oral mucosal ulceration (L) 1299

Disorders, loop, adverse reactions (A) 1012, congestive heart failure (A) 1011, continuous infusion (A) 1010, pharmacodynamics (A) 1011, pharmacology (A) 1010; torsemide, review (A) 396

Divalproex sodium, alopecia, zinc/selenium supplementation (L) 1302

Dobutamine, actual vs. ordered concentrations (RR) 1095

Doering, Paul, distinguished service professor, University of Florida (NC) 1321

Dopamine, actual vs. ordered concentrations (RR) 1095; low-dose, cirrhosis, renal insufficiency (L) 433, severe right heart failure, chronic obstructive pulmonary disease (CR) 493; no interaction, phenytoin (L) 1300; proarrhythmic effects (A) 271

Dornase alfa, cost, cystic fibrosis (RR) 459, (L) 1050

Dosage, amiodarone, atrial fibrillation (A) 600; bisoprolol (A) 411; dopamine, cirrhosis, renal insufficiency (L) 433; gentamicin, neonates (L) 430; granisetron (A) 1248; lamotrigine (L) 1173; midazolam, continuous infusion, morphine-induced myoclonus (CR) 25; ondansetron, children with leukemia (RR) 16; piperacillin/tazobactam (A) 511, kidney failure (L) 1051; rimantadine (A) 307; torsemide (A) 400; trimethoprim/sulfamethoxazole, kidney failure (L) 1300, venlafaxine (A) 392

Dosage form, aerosol, heparin, asthma (A) 71, rimantadine (A) 304, sympathomimetics, bronchial hyperactivity (RR) 848; intramuscular, diclofenac, necrosis, fasciitis (CR) 264, ketorolac tromethamine, gastrointestinal complications, elderly (CR) 698; intramuscular, apomorphine (A) 286; intraperitoneal, cisplatin, anaphylaxis (CR) 260; intravenous, amphotericin

B, lipid-emulsion vs. conventional (RR) 1197, continuous infusion, antibiotics (A) 415, haloperidol (CR) 690, piggyback vs. controlled-release (RR) 465, rifampin, pruritus (CR) 267; liquid, cisapride, stability (RR) 125; ocular, metipranolol, pulmonary edema (CR) 370; oral, flumazenil, epilepsy (A) 530; rectal, apomorphine (A) 285; subcutaneous, apomorphine (A) 284, continuous infusion, heparin (CR) 710; sublingual, apomorphine (A) 285; suspension, hydrocortisone, stability (RR) 987, itraconazole, serum concentrations (CR) 140; topical, famagillin, microsporidial keratoconjunctivitis (CR) 872, nonsteroidal antiinflammatory drugs, soft tissue injury (A) 780; transdermal, fentanyl, disposal (RR) 969, nicotine, Alzheimer's disease (A) 314

Dosage schedules, clindamycin, parenteral, meta-analysis (RR) 852; once daily, gentamicin, pharmacokinetics (RR) 117; two- vs. four-hour infusion, amphotericin B (RR) 1081

Drug administration, amphotericin B in dextrose, rapid infusion (A) 523; central venous access device, phenytoin precipitate, sodium bicarbonate (CR) 707; tobramycin, controlled-release vs. piggyback infusion (RR) 465

Drug information, pregnancy, lactation (L) 632; public-access computer bulletin board (RR) 1224

Drug information rounds, adenosine, acute theophylline intoxication (A) 1285; alprazolam, tinnitus (A) 311; asthma, heparin inhalation (A) 71; bone marrow transplant, antifungal prophylaxis (A) 921; calcium antagonists, extrapyramidal symptoms (A) 73, radiocontrast-associated nephrotoxicity (A) 187; cisapride, chronic idiopathic constipation (A) 1161; clenbuterol, athletic performance (A) 75; flumazenil, oral, epilepsy (A) 530; gabapentin, amyotrophic lateral sclerosis (A) 1160; ketoconazole, prophylaxis, acute respiratory distress syndrome (A) 784; lamotrigine, amyotrophic lateral sclerosis (A) 1160; mesna, hemorrhagic cystitis prophylaxis (A) 918; Lorenzo's oil, adrenoleukodystrophy (A) 312; minocycline, rheumatoid arthritis (A) 186; misoprostol, tinnitus (A) 782; nicotine, Alzheimer's disease (A) 314; nonsteroidal antiinflammatory drugs, topical, soft tissue injury (A) 780; ondansetron, smoking cessation (A) 1041; opioids, local analgesia (A) 189; pyrilium, hypercholesterolemia (A) 625; recombinant erythropoietin, zidovudine-induced anemia (A) 778; selective serotonin reuptake inhibitors, withdrawal syndrome (A) 1284; trimethoprim/sulfamethoxazole (A) 427; valproate, status epilepticus (A) 1042; vitamin E, coronary artery disease (A) 531; xanthine, interference with dipyrindomethalium-201 myocardial imaging (A) 425; zidovudine, maternal HIV transmission (A) 1287

Drug interactions, antihypertensives-antipsychotics (A) 603 antiinflammatory drugs, nonsteroidal-warfarin (A) 1274, (E) 1289

Antipsychotics-antihypertensives (A) 603

aspirin-warfarin (A) 1276

azithromycin-food (A) 913

benzodiazepines-erythromycin (A) 909

captopril-chlorpromazine (A) 606

carbamazepine-clarithromycin (A) 909

carbamazepine-erythromycin (A) 907

carbamazepine-flurithromycin (A) 912

carbamazepine-josamycin (A) 912

carbamazepine-miocamycin (A) 913

chloridazepoxide-nicotine (A) 1142

chlorpromazine-captopril (A) 606

chlorpromazine-guanethidine (A) 607

chlorpromazine-methylglucoside (A) 606

chlorpromazine-propranolol (A) 605

cimetidine-cyclosporine (RR) 1088

clarithromycin-carbamazepine (A) 909

clarithromycin-didanosine (A) 910

clarithromycin-digitalis (A) 910

clarithromycin-rifabutin (A) 1152

clarithromycin-terfenadine (A) 909

clarithromycin-theophylline (A) 909

clarithromycin-zidovudine (A) 910

clonidine-haloperidol (A) 605

clozapine-enalapril (A) 606

contraceptives, oral-nicotine (A) 1144

cyclosporine-cimetidine (RR) 1088

cyclosporine-erythromycin (A) 908

cyclosporine-famotidine (RR) 1088

cyclosporine-josamycin (A) 912

cyclosporine-miocamycin (A) 913

cyclosporine-roxithromycin (A) 911

cyclosporine-erythromycin (CR) 127

cyclosporine-isoniazid (CR) 127

cyclosporine-rifampin (CR) 127

dexamethasone-phenytoin (L) 935

diazepam-nicotine (A) 1142

didanosine-clarithromycin (A) 910

diffusional-warfarin (A) 1276

digitalis-clarithromycin (A) 910

digoxin-erythromycin (A) 908

dipyridamole, with thallium-201-pentoxifylline (A) 425

dirithromycin-theophylline (A) 911

enalapril-clozapine (A) 606

erythromycin-benzodiazepines (A) 909

erythromycin-carbamazepine (A) 907

erythromycin-cyclosporine (A) 908

erythromycin-digoxin (A) 908

erythromycin-methylprednisolone (A) 909

erythromycin-terfenadine (A) 908

erythromycin-theophylline (A) 907
 erythromycin-warfarin (A) 908
 erythromycin-cyclosporine (CR) 127
 etodolac-warfarin (A) 1276
 famotidine-cyclosporine (RR) 1088
 fenbupren-warfarin (A) 1276
 flecainide-nicotine (A) 1141
 fluconazole-rifabutin (A) 1152
 fluconazole-rifampin (CR) 994
 fluoxetine-itraconazole (L) 1048
 fluoxetine-terfenadine (L) 937
 flurithromycin-carbamazepine (A) 912
 flurithromycin-food (A) 912
 folic acid-phenytoin (A) 726
 food-azithromycin (A) 913
 food-flurithromycin (A) 912
 guanethidine-chlorpromazine (A) 607
 haloperidol-clonidine (A) 605
 haloperidol-methyldopa (A) 606
 ibuprofen-warfarin (A) 1276
 indomethacin-warfarin (A) 1276
 insulin-nicotine (A) 1141
 isoniazid-cyclosporine (CR) 127
 isoniazid-vincristine (L) 201
 itraconazole-fluoxetine (L) 1048
 josamycin-carbamazepine (A) 912
 josamycin-cyclosporine (A) 912
 josamycin-theophylline (A) 912
 ketoprofen-warfarin (A) 1276
 ketorolac-warfarin (A) 1277
 lamotrigine, review (A) 148
 leucovorin-phenytoin (L) 1303
 loxamican-warfarin (A) 1277
 mefenamic acid-warfarin (A) 1277
 methyldopa-chlorpromazine (A) 606
 methyldopa-haloperidol (A) 606
 methylprednisolone-erythromycin (A) 909
 miocamycin-carbamazepine (A) 913
 miocamycin-cyclosporine (A) 913
 nabumetone-warfarin (A) 1277
 nicotine-chlordiazepoxide (A) 1142
 nicotine-contraceptives, oral (A) 1144
 nicotine-diazepam (A) 1142
 nicotine-flecainide (A) 1141
 nicotine-insulin (A) 1141
 nicotine-propoxyphene (A) 1141
 nicotine-propranolol (A) 1142
 nicotine-tacrine (A) 1141
 nicotine-theophylline (A) 1140
 nimesulide-warfarin (A) 1277
 omeprazole, review (A) 1258
 pentoxifylline-dipyridamole-thallium-201 (A) 425
 phenobarbital-phenytoin (L) 83
 phenylbutazone-warfarin (A) 1277
 phenytoin-dexamethasone (L) 935
 phenytoin-folic acid (A) 726
 phenytoin-leucovorin (L) 1303
 phenytoin-phenobarbital (L) 83
 pindolol-thioridazine (A) 605
 propoxyphene-nicotine (A) 1141
 propranolol-chlorpromazine (A) 605
 propranolol-nicotine (A) 1142
 propranolol-thioridazine (A) 604
 ranitidine-clarithromycin (A) 910
 rifabutin-clarithromycin (A) 910, (A) 1152
 rifabutin-fluconazole (A) 1152
 rifampin-fluconazole (CR) 994
 rifampin-cyclosporine (CR) 127
 rokitamycin-theophylline (A) 912
 roxithromycin-cyclosporine (A) 911
 roxithromycin-theophylline (A) 911
 sulindac-warfarin (A) 1277
 tacrine-nicotine (A) 1141
 tenoxicam-warfarin (A) 1277
 terfenadine-clarithromycin (A) 909
 terfenadine-erythromycin (A) 908
 terfenadine-fluoxetine (L) 937
 thallium-201, with dipyridamole-pentoxifylline (A) 425
 theophylline-clarithromycin (A) 909
 theophylline-diltiazem (A) 911
 theophylline-erythromycin (A) 907
 theophylline-joamycin (A) 912
 theophylline-nicotine (A) 1140
 theophylline-rokitamycin (A) 912
 theophylline-roxithromycin (A) 911
 thioridazine-pindolol (A) 605
 thioridazine-propranolol (A) 604
 vincristine-isoniazid (L) 201
 warfarin-antiinflammatory drugs, nonsteroidal (A) 1274, (E) 1289
 warfarin-aspirin (A) 1276
 warfarin-diflunisal (A) 1276
 warfarin-erythromycin (A) 908
 warfarin-etodolac (A) 1276
 warfarin-fenbupren (A) 1276
 warfarin-ibuprofen (A) 1276
 warfarin-indomethacin (A) 1276
 warfarin-ketoprofen (A) 1276
 warfarin-ketorolac (A) 1277

warfarin-loxoxicam (A) 1277
 warfarin-mefenamic acid (A) 1277
 warfarin-nabumetone (A) 1277
 warfarin-naproxen (A) 1277
 warfarin-nimesulide (A) 1277
 warfarin-phenylbutazone (A) 1277
 warfarin-sulindac (A) 1277
 warfarin-tenoxicam (A) 1277
 zidovudine-clarithromycin (A) 910
Drug interactions and reactions, macrolides-azalides (A) 906
Drug reactions, rifabutin, urethritis (A) 1149
Drug selection perspectives, desogestrel (A) 736; fluvastatin (A) 743; gestodene (A) 736; hydroxymethylglutaryl-coenzyme A reductase inhibitors (A) 743; lovastatin (A) 743; norgestimate (A) 736; pravastatin (A) 743
Drug Surveillance Network, adverse reaction reporting (RR) 240
Drug utilization, acute myocardial infarction, Italy (RR) 1100
Drug withdrawal, selective serotonin reuptake inhibitors (A) 1284
**Drugs, adverse reactions, acetohefen, leukocytoclastic vasculitis, hemoptysis (L) 1168; bisoprolol, review (A) 411; clozapine, angina pectoris (CR) 138; bumetanide, review (A) 1012; bupropion, eosinophilia (CR) 867; calcium-channel blockers, extrapyramidal symptoms (A) 73; carbamazepine, Stevens-Johnson syndrome (L) 538; cefadroxil, liver disorder (CR) 875; cholestyramine, acidosis, hyperkalemia (L) 199; cinnarizine, extrapyramidal symptoms (A) 73; ciprofloxacin, Henoch-Schönlein purpura (L) 84, hepatotoxicity (CR) 257, hypertension, infant (L) 1049; cisplatin, anaphylaxis (CR) 260, angina pectoris (CR) 138; clarithromycin, delirium (CR) 486; computer monitoring (L) 788; cyproterone, hepatotoxicity (L) 634; desogestrel (A) 736; diclofenac, autoimmune hemolytic anemia (L) 787, necrosis, fasciitis (CR) 264, thrombocytopenia, neutropenia (CR) 713; diltiazem, erythema multiforme, elevated hepatic enzymes (L) 317, extrapyramidal symptoms (A) 74; dipyridamole, oral mucosal ulceration (L) 1299; diuretics, loop, review (A) 1012; divalproex sodium, alopecia (L) 1302; enalapril, angioneurotic edema (L) 317; erythromycin, hypotension (L) 934; etoposide, angina pectoris (CR) 138; famotidine, hyperprolactinemia, galactorrhea (L) 788; felbamate, delayed anaphylaxis (L) 430; fludaxamine, ototoxicity (L) 200; flunarizine, extrapyramidal symptoms (A) 73; fluvastatin, review (A) 751; gabapentin, weight gain (L) 1048; gemtamicin, ototoxicity (L) 200; gestodene, review (A) 738; granisetron, review (A) 1247; hydrochlorothiazide, acute pulmonary edema (CR) 701; hydroxyurea, fever (CR) 132; ifosfamide, Fanconi syndrome (CR) 590, nonconvulsive status epilepticus (CR) 1237; indapamide, hyponatremia, hypokalemia (A) 1124; ketorolac, death (L) 1299; ketorolac tromethamine, gastrointestinal complications (CR) 698; lactate, oral, panic disorder (L) 539; lamotrigine, review (A) 147; lorazepam, with polyethylene glycol, nephrotoxicity (CR) 1110; lovastatin, review (A) 751; metipranolol, pulmonary edema (CR) 370; metoclopramide, sinus arrest (CR) 381; misoprostol, tinnitus (A) 782; morphine, involuntary muscle hyperactivity (CR) 1118; nonsteroidal antiinflammatory drugs, asthma (L) 199; norgestimate (A) 738; omeprazole, exfoliative dermatitis (L) 82, review (A) 1258; paromomycin, pancreatitis in AIDS (CR) 22; piperacillin, with tazobactam, hypersensitivity (L) 936; piroxicam, reporting (RR) 676; polyethylene glycol, with electrolyte lavage solution, exacerbation of congestive heart failure (CR) 1232, with lorazepam, nephrotoxicity (CR) 1110; pravastatin, review (A) 751; prazosin, polyarthralgia (L) 937; propafenone, transient global amnesia (CR) 586; quinidine, arrhythmias (CR) 33; quinsarin/dalfopristin, review (A) 1025; ranipril, angioedema (L) 431; reporting (RR) 240, Rhode Island pharmacists (RR) 365; rifampin, pruritus (CR) 267; rimantadine, review (A) 305; risperidone, review (A) 615; simvastatin, review (A) 751; spiroglactone, acidosis, hyperkalemia (L) 199; steroids, invasive aspergillosis (CR) 1235; sulfamethoxazole, with trimethoprim, hyperkalemia (A) 427, liver disorder (CR) 875; sulindac, reporting (RR) 676; sulpiride, review (A) 156; sympathomimetics, premature labor (A) 518; tazobactam, with piperacillin, hypersensitivity (L) 936; ticlopidine, cholestatic hepatitis (CR) 30, granulomatous hepatitis (L) 633; toremide, review (A) 399; trimethoprim, with sulfamethoxazole, hyperkalemia (A) 427, liver disorder (CR) 875; valproate sodium, increased serum alkaline phosphatase (L) 539; venlafaxine, review (A) 391; verapamil, extrapyramidal symptoms (A) 74, hyperprolactinemia (CR) 999; vigabatrin, psychosis (CR) 1115; zidovudine, anemia (A) 778
Dukes, George E., president-elect, American College of Clinical Pharmacists (NC) 336**

E

Economics, see Pharmacoeconomics

Editorials, see also, An Opinion; Burnakis, Thomas G., Another Perspective on Monitoring Anticoagulation Therapy, 1045; Gidycz, Barry E., Garnett, William R., Perspective on Lamotrigine, 191; Lucas, B. Daniel Jr., Hilleman, Daniel E., Media Sensationalism of Clinical Trials: Freedom of Information or Potential for Causing Patient Harm? 629; Whitney, Harvey AK Jr., Influencing the Destiny of Pharmacy, 1297

Education, doctor of pharmacy, nontraditional, guidelines (NC) 1069; graduate, pharmacoepidemiology (L) 1169; residencies, fellowships, US, Canada (A) 1028
Education and training, baccalaureate vs. entry-level doctor of pharmacy graduates, activities, attitudes (RR) 977
Elimination, morphine, hemodialysis (L) 941; theophylline, hemofiltration (L) 787; trimethoprim/sulfamethoxazole, kidney failure (L) 1300
Ellsworth, Allan J., Bristol-Myers Squibb Family Medicine Research Award (NC) 960
Emergency services, cocaine determination (L) 82; use, migraine, asthma patients, health maintenance organization (RR) 251
Enalapril, angioneurotic edema (L) 317; interaction, clozapine (A) 606
Endocrinology, diabetes, risk factors, Arab Americans (RR) 573; peripheral diabetic neuropathy (A) 769
Enterococcus, resistance (A) 1035
Eosinophilia, bupropion (CR) 867
Epilepsy, lamotrigine, review (A) 144; commentary (E) 191
Epinephrine, actual vs. ordered concentrations (RR) 1095; proarrhythmic effects (A) 272
Equipment, infusion pumps, evaluation, morphine infusion (RR) 972
Erstad, Brian L., chair, American Society of Health-System Pharmacists Section of Clinical Specialists (NC) 1321; 1994 Clinical Educator Award (NC) 336
Erythromycin, hypotension (L) 934; interaction, benzodiazepines (A) 909, carbamazepine (A) 907, cyclosporine (CR) 127, (A) 908, digoxin (A) 908, methylprednisolone (A) 909, terfenadine (A) 908, theophylline (A) 907, warfarin (A) 908
Erythropoietin, clinical studies (A) 168; cost (A) 170; pharmacokinetics (A) 168; pharmacology (A) 168; recombinant, zidovudine-induced anemia (A) 778; review (A) 166
Ethics, American Pharmaceutical Association Code of Ethics for Pharmacists approved (NC) 111; rationing high-cost drugs (O) 78
Etodolac, interaction, warfarin (A) 1276
Etoposide, with cisplatin, bleomycin, angina pectoris (CR) 138
Ette, Eze, fellow, American College of Clinical Pharmacy (NC) 960

F

Fagan, Susan C., associate chair, Department of Pharmacy Practice, Wayne State University (NC) 1321
Falls, related to medication use, elderly (RR) 354
Famotidine, hyperprolactinemia, galactorrhea (L) 788; intravenous, gastric acid secretion (RR) 349; intravenous push, cost savings (L) 316; no interaction, cyclosporine (RR) 1088
Felbamate, delayed anaphylaxis (L) 430
Fellowships and Residencies, Arizona, University of Arizona, 648; California, University of Southern California, 1314; Canada, statistical data (A) 1028; Georgia, Mercer University, 1064; New York, Veterans Affairs Medical Center, 548; Texas, Veterans Affairs Medical Center, 216; Texas, Veterans Affairs Medical Center, 329; United States, statistical data (A) 1028
Fenbupren, interaction, warfarin (A) 1276
Fenfluramine, autism (A) 51
Fentanyl, transdermal, disposal (RR) 969
Fever, hydroxyurea (CR) 132
Filtration, hemo-, theophylline clearance (L) 787
Flavonoids, dietary, atherosclerosis (A) 627
Flecainide, interaction, nicotine (A) 1141
Fletcher, Courtney V., nominated for appointment, public advisory committee, FDA (NC) 336
Fluconazole, compared with ketoconazole, salivary concentrations (RR) 10; interaction, rifabutin (A) 1152, rifampin (CR) 994; pharmacokinetics, with/without rifampin (CR) 994; prophylaxis, bone marrow transplant (A) 921
Fludaxamine, with gentamicin, ototoxicity (L) 200
Flunarizine, oral, epilepsy (A) 530
Flunarizine, extrapyramidal symptoms (A) 73
Fluorescein, assay interference (L) 1052
Fluoxetine, autism (A) 51; diabetic peripheral neuropathy (A) 773; interaction, itraconazole (L) 1048, terfenadine, cardiac toxicity (L) 937
Fluvastatin, adverse reactions (A) 751; chemistry (A) 744; compared with lovastatin (A) 746; cost (A) 754; pharmacokinetics (A) 744; pharmacology (A) 744; review (A) 743
Flavoxamine, autism (A) 51; withdrawal syndrome (A) 1285
Folic acid, interaction, phenytoin (A) 726
Food, interaction, azithromycin (A) 913
Food and Drug Administration, guidelines, stereoisomers (A) 164; informed consent amendment (NC) 1321; regulations, pediatric use labeling (NC) 1070
Formulary forum, bisoprolol (A) 403; granisetron (A) 1240; lamotrigine (A) 144; piperacillin/tazobactam (A) 501; rimantadine (A) 299; toremide (A) 396; venlafaxine (A) 387
Franchise, Gloria Niemeyer, Donald E. Franchise Medal (NC) 960
Fumagillil, topical, microsporidial keratoconjunctivitis (CR) 872
Furosemide, adverse reactions (A) 1012; chronic kidney failure (A) 1011; compared with toremide, congestive heart failure (A) 397; continuous infusion, cardiac surgery (A) 1012, con-

gestive heart failure (A) 1011; cyclophosphamide-induced antidiuresis (A) 1012

G

Gabapentin, amyotrophic lateral sclerosis (A) 1160, (O) 1164; weight gain (L) 1048
Gamma-linolenic acid, diabetic peripheral neuropathy (A) 774
Gangliosides, diabetic peripheral neuropathy (A) 774
Gastroenterology, omeprazole, gastroesophageal reflux disease (A) 1252
Gastroesophageal reflux disease, review (A) 1252; omeprazole (A) 1255
Gemfibrozil, hyperlipidemia, solid organ transplant (A) 884
General medicine, fentanyl, transdermal, disposal (RR) 969; glutathione (A) 1263; hypertension, patient modification of therapy (RR) 1213
Gentamicin, dosage, neonates (L) 430; pharmacokinetics, open fractures (RR) 117; with fludaxone, ototoxicity (L) 200; with vancomycin/rifampin, methicillin-resistant *Staphylococcus aureus* osteomyelitis (CR) 694
Geriatrics, antileptic drugs, prescribing patterns, Nova Scotia (RR) 576; falls, related to medication use (RR) 354; hydrochlorothiazide, acute pulmonary edema (CR) 701; influenza vaccine, recommendations (NC) 959; ketorolac tromethamine, intramuscular, gastrointestinal complications (CR) 698; medication-taking behavior, high- vs. low-functioning elderly (RR) 359; peripheral vascular disease, assessment (RR) 671; pneumococcal vaccine, recommendations (NC) 959, vaccination rates (NC) 1319; psychometric profiling, Cambridge Cognitive Examination (RR) 982
Gerontology, adverse reactions (A) 738; pharmacokinetics (A) 737
Glutathione, antioxidant (A) 1266; detoxification (A) 1265; review (A) 1263
Glutamine, review (A) 175
Granisetron, adverse reactions (A) 1247; nausea, vomiting, pediatrics (A) 68; pharmacokinetics (A) 1241; pharmacology (A) 1241; dosage (A) 1248; review (A) 1240
Growth hormone, review (A) 177
Guanethidine, interaction, chlorpromazine (A) 607

H-J

HIV, see **Human immunodeficiency virus**
HIV and AIDS, attitudes, knowledge, Arizona pharmacists (RR) 1218; toxoplasmosis (A) 760
HMG-CoA reductase inhibitors, see **Hydroxymethylglutaryl-coenzyme A reductase inhibitors**
Haloperidol, autism (A) 51; compared with sulpiride, schizophrenia (A) 155; compatibility, diphenhydramine (L) 1168; continuous infusion, intensive care delirium (CR) 690; interaction, clonidine (A) 605, methylodopa (A) 606; intermittent porphyria (L) 200
Haloperidol decanoate, (RR) 663; hyponatremia (RR) 663
Hantavirus pulmonary syndrome, diagnosis, treatment (A) 61; epidemiology (A) 58; pathogenesis (A) 59
Health maintenance organizations, emergency department use, migraine, asthma patients (RR) 251
Heart failure, congestive, bioelectrical impedance analysis (RR) 1091; exacerbation, polyethylene glycol-electrolyte lavage solution (CR) 1232; furosemide, continuous infusion (A) 1011
Haemophilus influenzae type b, elimination (NC) 1319
Hemochromatosis, ciprofloxacin (L) 84
Heparin, continuous subcutaneous infusion, Trousseau's syndrome (CR) 710; inhalation, asthma (A) 71; low-molecular-weight, pharmacology (A) 900; monitoring, activated clotting time vs. activated partial thromboplastin time (A) 1015, activated clotting time vs. partial thromboplastin time (E) 1045; pharmacology (A) 899
Hepatitis, cholestatic, ticlopidine (CR) 30; granulomatous, ticlopidine (L) 633
Hepatotoxicity, ciprofloxacin (CR) 257; cyproterone (L) 634; fatal, amiodarone (CR) 582
Hilleman, Daniel E., fellow, American College of Clinical Pharmacy (NC) 960
Hirudins, pharmacology (A) 901
Human immunodeficiency virus, attitudes, knowledge, Arizona pharmacists (RR) 1218; counseling, testing (NC) 550; maternal transmission, zidovudine (A) 1287
Hydrochlorothiazide, acute pulmonary edema (CR) 701
Hydrocortisone, oral suspension, stability (RR) 987
Hydroxymethylglutaryl-coenzyme A reductase inhibitors, adverse reactions (A) 751; chemistry (A) 744; comparative data, lack (L) 1304; cost (A) 754; hyperlipidemia, solid organ transplant (A) 886; pharmacokinetics (A) 744; pharmacology (A) 744; review (A) 743
Hydroxyurea, fever (CR) 132
Hypercholesterolemia, children, bile acid sequestrants (A) 68; prevalence, Nova Scotia, geriatrics (RR) 576; pyllium (A) 625
Hyperhidrosis, propantheline bromide (CR) 489

Hyperlipidemia, solid organ transplant (A) 879, bile acid sequestrants (A) 885, cyclosporine (A) 882, gemfibrozil (A) 884, hydroxymethylglutaryl-coenzyme A reductase inhibitors (A) 886, niacin (A) 885
Hypertension, ciprofloxacin, infant (L) 1049; patient modification of therapy (RR) 1213; pulmonary, pediatrics, nitric oxide (A) 66
Hypokalemia, indapamide (CR) 1124
Hyponatremia, haloperidol decanoate (RR) 663; indapamide (CR) 1124
Hypotension, erythromycin (L) 934
Hypothyroidism, levothyroxine brand interchange (CR) 482
Ibuprofen, interaction, warfarin (A) 1276; simulated overdose, whole bowel irrigation, fluid volume comparison (RR) 246; toxicity, pediatrics (CR) 869
Ifosfamide, Fanconi syndrome (CR) 590; nonconvulsive status epilepticus (CR) 1237
Imipenem, with cilastatin, compared with piperacillin/tazobactam (A) 507
Imipramine, compared with venlafaxine, major depression (A) 391
Immunization, 2-year-old children (NC) 550; recommended schedule (NC) 219
Immunoassay, fluorescence polarization, fluorescein interference (L) 1052, serum digoxin, itraconazole (L) 938
Immunology, colony-stimulating factor, surveillance of use (RR) 475
Immunomodulators, infectious diseases (A) 1037
Indapamide, hyponatremia, hypokalemia (CR) 1124
Indomethacin, interaction, warfarin (A) 1276; premature labor (A) 519
Infectious diseases, amphotericin B, lipid-emulsion vs. conventional administration (RR) 1197, toxicology, dosage regimens (RR) 1081; antibiotics, beta-lactam, continuous infusion (A) 415, dosage adjustment, kidney failure (RR) 1202, step-down therapy, pharmacoeconomic benefit (RR) 561; antifungals, peptic ulcer disease (A) 1035; clindamycin dosing regimens, meta-analysis (RR) 852; gentamicin, pharmacokinetics, open fractures (RR) 117; hantavirus pulmonary syndrome (A) 57; immunomodulators (A) 1037; ketoconazole, fluconazole, salivary concentrations (RR) 10
Influenza, incidence (NC) 650
Influenza A, rimantadine, review (A) 299
Influenza vaccine, recommendations, elderly (NC) 959
Insulin, interaction, nicotine (A) 1141
Insulin-like growth factor, review (A) 178
International Consensus Meeting Criteria, drug-induced liver disorders (CR) 875
International reports, Italy, drug utilization, acute myocardial infarction (RR) 1100; Japanese pharmacy (A) 181; Nova Scotia, antileptic drugs, prescribing patterns, geriatrics (RR) 576; South Africa, prescribing, analgesics (L) 1302; Sweden, antidepressant use (RR) 566
Itraconazole, interaction, fluoxetine (L) 1048
Irrigation, whole bowel, polyethylene glycol, fluid volume comparison (RR) 246
Isoniazid, interaction, cyclosporine (CR) 127, vincristine (L) 201
Italy, drug utilization, acute myocardial infarction (RR) 1100
Itraconazole, fluorescence polarization immunoassay, serum digoxin (L) 938; suspension, serum concentrations (CR) 140
Japan, clinical trial flaws, anxiolytics (L) 432; pharmacy practice (A) 181
Josamycin, interaction, carbamazepine (A) 912, cyclosporine (A) 912, theophylline (A) 912
Journal review, Journal of Chronic Fatigue Syndrome (NG) Klimas, R Patacar, 1057
Journals, economic evaluations, quality assessment (RR) 681

K-M

Kane, Bernard "Bud" J., obituary (NC) 960
Kelly, H. William, National Asthma Education and Prevention Program Expert Panel (NC) 1070; nominated for appointment, public advisory committee, FDA (NC) 336; Pulmonary-Allergy Drugs FDA Advisory Committee (NC) 960
Keratoconjunctivitis, microsporidial, topical fumagillin (CR) 872
Ketoconazole, compared with fluconazole, salivary concentrations (RR) 10; prophylaxis, acute respiratory distress syndrome (A) 784
Ketorolac, fatality (L) 1299
Ketorolac, interaction, warfarin (A) 1276
Ketorolac tromethamine, intramuscular, gastrointestinal complications, elderly (CR) 698
Keys, Paddy J., assistant professor, Department of Pharmacy Practice, Wayne State University (NC) 1321
Kidney failure, antibiotics, dosage adjustment (RR) 1202; chronic, bumetanide, continuous infusion (A) 1012, furosemide, continuous infusion (A) 1011; piperacillin/tazobactam, dosage (L) 1051
Krelling, David H., outstanding accomplishments, American Association of Colleges of Pharmacy (NC) 1070
Lactate, oral, panic disorder (L) 539
Lamotrigine, adverse reactions (A) 147; amyotrophic lateral

sclerosis (A) 1160; chemistry (A) 144; clinical experience (E) 191; clinical studies (A) 146; dosage (A) 148, (L) 1173; drug interactions (A) 148; pharmacokinetics (A) 145; pharmacology (A) 145; review (A) 144; toxicology (A) 145
Latisolai, Clifton J., obituary (NC) 814
Leucovorin, interaction, phenytoin (L) 1303; with trimetrexate, toxoplasmosis (A) 765
Leukemia, children, reduced-dose ondansetron (RR) 16
Levothyroxine, brand interchange, therapeutic failure (CR) 482, (L) 1049
Lidocaine, diabetic peripheral neuropathy (A) 774
Lipids, concentrations, ascorbic acid (A) 1129
Lithium, effect on water handling (L) 1304
Lomustine, multiorgan failure (CR) 384
Lorazepam, with polyethylene glycol, nephrotoxicity (CR) 1110
Lorenzo's oil, adrenoleukodystrophy (A) 312
Lovastatin, adverse reactions (A) 751; chemistry (A) 744; compared with fluvastatin (A) 746; compared with pravastatin (A) 746; compared with simvastatin (A) 748; cost (A) 754; pharmacokinetics (A) 744; pharmacology (A) 744; review (A) 743
Lyme disease, incidence (NC) 959
Lymphopene, carbamazepine (CR) 865
Magnesium sulfate, premature labor (A) 519
Malaria, intravenous quinine, arrhythmias (CR) 33
Managed care, emergency department use, migraine, asthma (RR) 251
Matzke, Gary, Russell R. Miller Award, American College of Clinical Pharmacy (NC) 960
McGhan, William F., Board of Directors, American Association of Colleges of Pharmacy (NC) 1070
Media, sensationalism (E) 629
Melanoma, mortality (NC) 811
Meperidine hydrochloride, compatibility, ondansetron hydrochloride (RR) 1106
Mesna, hemorrhagic cystitis prophylaxis (A) 918
Methodology, meta-analysis, clindamycin dosing regimens (RR) 852
Methoxamine, proarrhythmic effects (A) 276
Methyl salicylate, medicated oils, toxicity (L) 1301
Methyldopa, interaction, chlorpromazine (A) 606, haloperidol (A) 606
Methylphenidate, autism (A) 51
Methylprednisolone, interaction, erythromycin (A) 909; pharmacokinetics, renal transplant (RR) 120
Mesipranolol, ocular, pulmonary edema (CR) 370
Metoprolol, sinus arrest (CR) 381
Mexiletine, diabetic peripheral neuropathy (A) 774
Midazolam, continuous infusion, morphine-induced myoclonus (CR) 25
Migraine, emergency department use, health maintenance organization (RR) 251
Mincycline, rheumatoid arthritis (A) 186
Miocamycin, interaction, carbamazepine (A) 913, cyclosporine (A) 913
Misoprostol, tinnitus (A) 782
N^G-Methyl-L-arginine, septic shock (A) 36
Morphine, continuous infusion (RR) 972; elimination, hemodialysis (L) 941; involuntary muscle hyperactivity (CR) 1118; local analgesia (A) 189; myoclonus, continuous midazolam infusion (CR) 25
Myocardial infarction, acute, drug utilization, Italy (RR) 1100

N-O

Naltrexone, autism (A) 51
Narcotics, related to falls, elderly (RR) 354
Nephrotoxicity, radiopharmaceuticals, calcium antagonist prophylaxis (A) 187; reporting (RR) 241
Neurology, apomorphine, Parkinson's disease (A) 282; phenytoin, concentrations, Scheiner-Tozer method, hypoalbuminemia (RR) 667, unbound concentrations, with valproic acid (RR) 470
Neutropenia, amphotericin B, lipid emulsion vs. conventional administration (RR) 1197; diclofenac (CR) 713; reporting (RR) 240
New drug developments, quinuapristin/dalfopristin (A) 1022; sulpiride (A) 152
Niacin, hyperlipidemia, solid organ transplant (A) 885
Nicotine, addiction, women (NC) 450; interaction, chlorzazepate (A) 1142, contraceptives, oral (A) 1144, diazepam (A) 1142, flunitrazepam (A) 1141, insulin (A) 1141, propoxyphene (A) 1141, propranolol (A) 1142, tacrine (A) 1141, theophylline (A) 1140; transdermal, Alzheimer's disease (A) 314
Nifedipine, compared with bisoprolol, essential hypertension (A) 410; prophylaxis, radiocontrast nephrotoxicity (A) 187
Nitrendipine, compared with bisoprolol, essential hypertension (A) 410; prophylaxis, radiocontrast nephrotoxicity (A) 187
Nitric oxide, pulmonary hypertension, pediatrics (A) 66; vasodilation, septic shock (A) 36
N^G-Nitro-L-arginine methyl ester, septic shock (A) 36
Norepinephrine, proarrhythmic effects (A) 274
Norgestrel, adverse reactions (A) 738; pharmacokinetics (A) 737

Q-S

- Nova Scotia, antileptic drugs, prescribing patterns, geriatrics (RR) 576
- Nutrition**, enteral, ranitidine hydrochloride stability (RR) 859; parenteral, indications (A) 174
- Obesity**, carbamazepine pharmacokinetics (RR) 843
- Obstetrics**, drug use, drug information center (L) 632; hospital stay (NC) 810; maternal mortality, black vs. white (NC) 334; tocolytic therapy (A) 515
- Olson, Keith M.**, fellow, American College of Clinical Pharmacy (NC) 960
- Omega-3 fatty acids**, review (A) 177
- Omeprazole**, adverse reactions (A) 1258; chemistry (A) 1255; compared with cimetidine, gastroesophageal reflux disease (A) 1256; compared with ranitidine, gastroesophageal reflux disease (A) 1256; cost (A) 1259; exfoliative dermatitis (L) 82; gastroesophageal reflux disease, review (A) 1252; interactions (A) 1258
- Oncology**, carbamazepine, lymphoma (CR) 865; morphine infusion, pump evaluation (RR) 972
- Ondansetron**, nausea, vomiting, pediatrics (A) 68; reduced dose, children with leukemia (RR) 16; smoking cessation (A) 1041
- Ondansetron hydrochloride**, compatibility, meperidine hydrochloride (RR) 1106
- Opinion**, see **An Opinion; Editorials**
- Opioids**, local analgesia (A) 189
- Orthopedics**, open fractures, gentamicin pharmacokinetics (RR) 117
- Osteomyelitis**, methicillin-resistant *Staphylococcus aureus*, vancomycin/rifampin/gentamicin (CR) 694; piperacillin/tazobactam, hypersensitivity (L) 936
- Oxytocin antagonists**, premature labor (A) 520
- P**
- Pancreatitis**, AIDS, paromomycin (CR) 22
- Panic disorder**, exacerbation, oral lactate (L) 539
- Parkinson's disease**, apomorphine (A) 282
- Paromomycin**, pancreatitis in AIDS (CR) 22
- Paroxetine**, withdrawal syndrome (A) 1284
- Pediatric critical care**, dopamine, dobutamine, epinephrine, actual vs. ordered concentrations (RR) 1095
- Pediatric oculochemistry**, chemotherapy-induced emesis, ondansetron (RR) 16
- Pediatric psychiatry**, autism, pharmacotherapy (A) 47
- Pediatrics**, carbamazepine, Stevens-Johnson syndrome (L) 538; ciprofloxacin, hypertension (L) 430; drug monographs, Canada (L) 1052; erythropoietin, review (A) 166; gentamicin dosage, neonates (L) 430; granisetron, nausea, vomiting (A) 68; *Haemophilus influenzae* type b, elimination (NC) 1319; hydrocortisone, oral suspension, stability (RR) 987; hypercholesterolemia, bile acid sequestrants (A) 68; ibuprofen toxicity (CR) 869; immunization, 2-year-old children (NC) 550; labeling, Food and Drug Administration regulations (NC) 1070; leukemia, reduced-dose ondansetron (RR) 16; nitric oxide, pulmonary hypertension (A) 66; ondansetron, nausea, vomiting (A) 68; perfluorocarbons, neonatal respiratory distress syndrome (A) 67; vaccination (A) 69; vigabatrin, psychosis (CR) 1115; vitamin E with cyclosporine, improved cyclosporine absorption (A) 67; zidovudine, maternal transmission of HIV (A) 1287
- Pediatrics and geriatrics**, cisapride, stability (RR) 125
- Pemoline**, autism (A) 51
- Pentoxifylline**, interaction, dipyrindamole-thallium-201 (A) 425
- Perfluorocarbons**, neonatal respiratory distress syndrome (A) 67
- Peripheral vascular disease**, assessment, geriatrics (RR) 671
- Personnel Placement**, see separate section, **ADVERTISEMENTS**
- Pertussis**, incidence (NC) 1069
- Pharmacodynamics**, antiinflammatory drugs, nonsteroidal drugs-warfarin interaction (A) 1275; beta-lactam antibiotics (A) 415; quinupristin/dalfopristin (A) 1025; stereoisomers (A) 161; warfarin-antiinflammatory drugs, nonsteroidal interaction (A) 1275
- Pharmacoeconomics**, claim substantiation (L) 942; cost, anti-neoplastic agents (A) 295; bisoprolol (A) 412; colony-stimulating factors (RR) 475; domatec alfa, cystic fibrosis (RR) 459, (L) 1050; erythropoietin (A) 170; famotidine intravenous push (L) 316; hydroxymethylglutaryl-coenzyme A reductase inhibitors (A) 754; infusion pumps (RR) 972, omeprazole (A) 1259, rationing high-cost drugs (O) 78, risperidone (A) 616, step-down therapy, from intravenous ceftriaxone to oral cefprozime proctil (RR) 561, tocolytic therapy (A) 520; journals, economic evaluations (RR) 681; statistics, confidence intervals, sample size calculations (A) 719
- Pharmacopidemiology**, adverse drug reactions, reporting (RR) 240, piroxicam, sulindac (RR) 676; antidepressants, use in Sweden (RR) 566; drug utilization, acute myocardial infarction, Italy (RR) 1100; graduate education (L) 1169; medication-taking behavior, high- vs. low-functioning elderly (RR) 359; postmarketing surveillance network, development (RR) 1208
- Pharmacokinetics**, aminoglycosides, variability (L) 939; anti-inflammatory drugs, nonsteroidal-warfarin interaction (A) 1275; apomorphine (A) 282; beta-lactam antibiotics (A) 418; bisoprolol (A) 407; carbamazepine, obese, lean subjects (RR) 943; cyclosporine, venous hemodialysis (CR) 374; cyclosporine 3450 enzymes (A) 619; desogestrel (A) 737; erythropoietin (A) 168; fluconazole, with/without rifampin (CR) 994; fluvastatin (A) 744; gentamicin, open fractures (RR) 117; gestodene (A) 737; granisetron (A) 1241; lamotrigine (A) 145; lovastatin (A) 744; methylprednisolone, renal transplant (RR) 120; norgestrel (A) 737; omeprazole (A) 1255; piperacillin/tazobactam (A) 505; pravastatin (A) 744; progesterins (A) 737; quinupristin/dalfopristin (A) 1024; rimantadine (A) 300; risperidone (A) 611; simvastatin (A) 744, heart transplant (RR) 235; stereoisomers (A) 161; sulpiride (A) 153; tobramycin, infusion methods compared (RR) 465; torsemide (A) 397; vancomycin, venous hemodialysis (CR) 374; venlafaxine (A) 388; warfarin-antiinflammatory drugs, nonsteroidal interaction (A) 1275
- Pharmacokinetics and pharmacodynamics**, stereochemistry (A) 161
- Pharmacology**, antithrombotic agents (A) 892; bisoprolol (A) 404; erythropoietin (A) 168; fluvastatin (A) 744; granisetron (A) 1241; heparin (A) 899, low-molecular-weight (A) 900; hirudin (A) 901; lamotrigine (A) 145; lovastatin (A) 744; pravastatin (A) 744; progesterins (A) 737; risperidone (A) 610; simvastatin (A) 744; sulpiride (A) 152; torsemide (A) 397; venlafaxine (A) 388; warfarin (A) 1274
- Pharmacotherapy**, asthma management program, emergency department visits (RR) 5; important events, predictions (E) 1292; organizations, coalition and single leader needed (E) 1297; recent advances, ambulatory care (A) 716;
- Pharmacy services**, Japan (A) 181; current status (A) 1156
- Pharmacy technicians**, national certification program (NC) 333
- Phenobarbital**, interaction, phenytoin (L) 273
- Phenylephrine**, proerythritic effects (A) 85
- Phenytoin**, concentrations, Scheiner-Tozer method, hypoalbuminemia (RR) 667, rebound, plasmapheresis (CR) 592, with valproic acid (RR) 470; diabetic peripheral neuropathy (A) 774; interaction, desmethadone (L) 935, folic acid (A) 726, leucovorin (L) 1303, phenobarbital (L) 83; no interaction, dopamine (L) 1300; precipitate dissolution, sodium bicarbonate (CR) 707
- Physicians**, with pharmacists, asthma management, emergency department visits (RR) 5
- Phytonadione**, reduction of INR (CR) 1228
- Pick's disease**, prophylaxis, therapy (L) 538
- Pierpaoli, Paul G.**, Harvey AK Whitney Lecture Award (NC) 651
- Piperacillin**, with tazobactam, compared with ceftazidime (A) 509, compared with imipenem/cilastatin (A) 507, compared with ticarcillin/clavulanate (A) 507, cost (A) 511; dosage (A) 511, kidney failure (L) 1051, hypersensitivity (L) 936, microbiology (A) 502, pharmacokinetics (A) 505, review (A) 501
- Piroxicam**, adverse reactions, reporting (RR) 676
- Plasmodium falciparum**, malaria, intravenous quinidine, arrhythmias (CR) 33
- Pneumococcal vaccine**, recommendations, elderly (NC) 959; vaccination rates, elderly (NC) 1319
- Polyarthralgia**, prazosin (L) 937
- Polyethylene glycol**, whole bowel irrigation, fluid volume comparison (RR) 246; with electrolyte lavage solution, exacerbation of congestive heart failure (CR) 1232; with lorazepam, nephrotoxicity (CR) 1110
- Porphyria**, intermittent, haloperidol (L) 200
- Postmarketing surveillance**, development (RR) 1208
- Pravastatin**, adverse reactions (A) 751; chemistry (A) 744; compared with lovastatin (A) 746; compared with simvastatin (A) 748; cost (A) 754; pharmacokinetics (A) 744; pharmacology (A) 744; review (A) 743
- Prazosin**, polyarthralgia (L) 937
- Pregnancy**, supraventricular tachycardia, adenosine (L) 938
- Prescribing**, analgesics, South Africa (L) 1302
- Probolol**, hyperlipidemia, solid organ transplant (A) 885
- Progesterins**, chemistry (A) 736; pharmacokinetics (A) 737; pharmacology (A) 737
- Propafenone**, transient global amnesia (CR) 586
- Propanteline bromide**, hyperhidrosis, spinal cord injury (CR) 489
- Prophylaxis**, antifungal, bone marrow transplant (A) 921; cefazolin, gastric restrictive surgery (L) 935; hemorrhagic cystitis, mesna (A) 918; ketoconazole, acute respiratory distress syndrome (A) 784; Pick's disease (L) 538; radiopharmaceutical nephrotoxicity, calcium antagonists (A) 187; rimantadine, influenza A (A) 303; vancomycin resistance (NC) 1187; vitamin E, coronary artery disease (A) 531
- Propoxyphene**, interaction, nicotine (A) 1141
- Propranolol**, autism (A) 51; interaction, chlorpromazine (A) 605, nicotine (A) 1142, thioridazine (A) 604
- Prostaglandin synthetase inhibitors**, premature labor (A) 519
- Pruritus**, rifampin (CR) 267
- Pseudomonas aeruginosa**, diarrhea, ciprofloxacin (CR) 1122
- Psychiatry**, haloperidol decanoate, water handling (RR) 663
- Psychosis**, child, vigabatrin (CR) 1115
- Pyllum**, hypercholesterolemia (A) 625
- Pulmonary and allergy**, asthma management program, pharmacist-managed (RR) 5
- Pyridoxine**, autism (A) 51
- Pyrimethamine**, toxoplasmosis (A) 761; with clarithromycin, toxoplasmosis (A) 765; with clindamycin, toxoplasmosis (A) 763; with dapsone, toxoplasmosis (A) 762; with sulfadiazine, toxoplasmosis (A) 762
- Quinidine**, intravenous, arrhythmias (CR) 33
- Quinupristin**, with dalfopristin, adverse reactions, review (A) 1025, chemistry (A) 1023, pharmacodynamics (A) 1024, pharmacokinetics (A) 1024, resistance (A) 1024
- Raasch, Ralph H.**, outstanding accomplishments, American Association of Colleges of Pharmacy (NC) 1070
- Race**, maternal mortality, black vs. white (NC) 334
- Radiopharmaceuticals**, nephrotoxicity, calcium antagonist prophylaxis (A) 187
- Ramipril**, angioedema (L) 431
- Ranitidine hydrochloride**, stability, enteral nutrient formulas (RR) 859
- Recombinant human DNase**, see **Dornase alfa**
- Residencies**, see **Fellowships**
- Resistance**, *Candida albicans* (A) 1037; *Enterococcus* (A) 1035; quinupristin/dalfopristin (A) 1024; *Streptococcus pneumoniae* (A) 1036; tuberculosis (A) 1037; vancomycin, prevention (NC) 1187
- Respiratory distress syndrome**, acute, epidemiology (A) 1002, ketoconazole prophylaxis (A) 784, review (A) 1002, treatment (A) 1004; neonatal, perfluorocarbons (A) 67
- Respiratory syncytial virus**, incidence (NC) 218
- Rho Chi Lecture Award**, pharmacy services (A) 1156
- Rhode Island**, adverse drug reaction reporting (RR) 365
- Rifabutin**, interaction, clarithromycin (A) 910, (A) 1152, fluconazole (A) 1152; uveitis (A) 1149
- Rifampin**, interaction, cyclosporine (CR) 127, fluconazole (CR) 994; pruritus (CR) 267; with vancomycin/gentamicin, methicillin-resistant *Staphylococcus aureus* osteomyelitis (CR) 694
- Rimantadine**, adverse reactions (A) 305; dosage (A) 307; pharmacokinetics (A) 300; review (A) 299
- Risperidone**, adverse reactions (A) 615; cost (A) 616; pharmacokinetics (A) 611; acting executive associate dean, University of Florida College of Pharmacy (NC) 336
- Roxithromycin**, interaction, cyclosporine (A) 911, theophylline (A) 911
- Schentag, Jerome J.**, APHA Stimulation of Research Award (NC) 220
- Schizophrenia**, risperidone (A) 610; sulpiride, review (A) 152
- Schroeder, Donna J.**, manager, Pharmacy Services, Axion, On-Care Health (NC) 814; outstanding accomplishments, American Association of Colleges of Pharmacy (NC) 1070
- Septic shock**, nitric oxide synthase inhibitors (A) 36
- Serotonin reuptake inhibitors**, selective, withdrawal syndrome (A) 1284
- Sertraline**, withdrawal syndrome (A) 1284
- Simvastatin**, pharmacokinetics, heart transplant (RR) 235
- Smith, Gary H.**, Elias Schlonsberg Award (NC) 336; chair-elect, Pharmacy Practice section, American Association of Colleges of Pharmacy (NC) 552
- Smoking**, adults, incidence (NC) 334; cessation, ondansetron (A) 1041; drug interactions (A) 1139; women (NC) 110
- Sodium bicarbonate**, dissolution, phenytoin precipitate (CR) 707
- Somatomedin C**, see **Insulin-like growth factor**
- South Africa**, prescribing, analgesics (L) 1302
- Spirometrolone**, acidosis, hyperkalemia (L) 199
- Stability**, cisapride, liquid dosage form (RR) 125; hydrocortisone (RR) 987
- Staphylococcus aureus**, methicillin-resistant, osteomyelitis, vancomycin/rifampin/gentamicin (CR) 694
- Statistics**, confidence intervals, sample size calculations, pharmacoeconomic studies (A) 719
- Status epilepticus**, nonconvulsive, ifosfamide (CR) 1237; valproate (A) 1042
- Stereoisomers**, pharmacokinetic, pharmacodynamic differences (A) 161
- Steroids**, cortico-, asthma, mild, chronic (L) 1170; invasive aspergillosis (CR) 1235
- Streptococcus pneumoniae**, resistance (A) 1036; vaccination rates, elderly (NC) 1319
- Stringer, Kathleen A.**, fellow, American College of Clinical Pharmacy (NC) 960
- Substance abuse**, nicotine, women (NC) 450
- Sulfadiazine**, with pyrimethamine, toxoplasmosis (A) 762
- Sulfamethoxazole**, with trimethoprim, dosage, kidney failure (L) 1300; hyperkalemia (A) 427, liver disorder (CR) 875, toxoplasmosis (A) 761
- Sulindac**, adverse reactions, reporting (RR) 676
- Sulpiride**, adverse reactions (A) 156; chemistry (A) 152; compared with chlorpromazine (A) 156; compared with haloperidol (A) 155; compared with trifluoperazine (A) 154; pharmacokinetics (A) 153; pharmacology (A) 152; review (A) 152
- Sumatriptan**, cyclic vomiting (CR) 997
- Surgery**, cardiac, famotidine, intravenous, effect on gastric secretion (RR) 349, furosemide, continuous infusion (A) 1012; compatibility, ondansetron hydrochloride/meperidine hydrochloride (RR) 1106; gastric restrictive, cefazolin prophylaxis (L) 935
- Sweden**, antidepressant use (RR) 566
- Sympatholysis**, bisoprolol, review (A) 403
- Sympathomimetics**, aerosolized, bronchial hyperactivity (RR) 848; pharmacokinetics, pregnancy (A) 516; premature labor (A) 516

T

- Tachycardia**, supraventricular, pregnancy, adenosine (L) 938
- Tacrine**, interaction, nicotine (A) 1141
- Tamoxifen**, node-negative breast cancer (A) 293
- Tazobactam**, with piperacillin, compared with ceftazidime (A) 509; compared with imipenem/cilastatin (A) 507; compared with ticarcillin/clavulanate (A) 507; cost (A) 511; dosage (A) 511; kidney failure (L) 1051; hypersensitivity (L) 936; microbiology (A) 502; pharmacokinetics (A) 505; review (A) 501
- Temperature**, cisapride stability (RR) 125
- Terfenadine**, interaction, clarithromycin (A) 909; erythromycin (A) 908; fluoxetine, cardiac toxicity (L) 937
- Tests**, bioelectrical impedance analysis, congestive heart failure (RR) 1091; laboratory, activated clotting time vs. activated partial thromboplastin time, heparin monitoring (A) 1015
- Thallium-201**, with dipyridamole, interaction, pentoxifylline (A) 425
- Theophylline**, acute intoxication, adenosine (A) 1285; clearance, hemofiltration (L) 787; interaction, clarithromycin (A) 909; diltiazem (A) 911; erythromycin (A) 907; josamycin (A) 912; nicotine (A) 1140; roxithromycin (A) 911
- Therapeutic controversies**, amphotericin B in dextrose, rapid infusion (A) 523; cancer, node-negative breast, adjuvant therapy (A) 289; loop diuretics, continuous infusion (A) 1010
- Therapeutic monitoring**, heparin, activated clotting time vs. activated partial thromboplastin time (A) 1015; activated clotting time vs. partial thromboplastin time (E) 1045
- Thioridazine**, interaction, propranolol (A) 604
- Thiothixene**, concentrations (L) 789
- Thompson, Dennis F**, fellow, American College of Clinical Pharmacy (NC) 960
- Thrombocytopenia**, critical care, risk factors (RR) 835; diclofenac (CR) 713
- Thrombolytics**, drug utilization, Italy (RR) 1100
- Ticarcillin**, with clavulanate, compared with piperacillin/tazobactam (A) 507
- Ticlopidine**, cholestatic hepatitis (CR) 30; granulomatous hepatitis (L) 633
- Tinidazole**, alprazolam (A) 311; misoprostol (A) 782
- Tolramycin**, hypersensitivity (CR) 704; pharmacokinetics, piggyback vs. controlled-release infusion (RR) 465
- Tocolytics**, review (A) 515
- Tolrestat**, diabetic peripheral neuropathy (A) 772
- Torsemide**, adverse reactions (A) 399; compared with furosemide, congestive heart failure (A) 397; dosage (A) 400; pharmacokinetics (A) 397; pharmacology (A) 397; review (A) 396
- Toxicity**, adverse drug reaction reporting, Rhode Island pharmacists (RR) 365; amiodarone (A) 599; amphotericin B, administration in fat emulsion (CR) 496; dosage regimens (RR) 1081; benzyl alcohol, with diazepam infusion (L) 632; ibuprofen, pediatrics (CR) 869; simulated overdose, whole bowel irrigation (RR) 246; lomustine, multiorgan failure (CR) 384; methyl salicylate, medicated oils (L) 1301; nephro-, polyethylene glycol/forazepam (CR) 1110; neurologic, cisplatin (CR) 134; venlafaxine (A) 388
- Toxoplasmosis**, acquired immunodeficiency syndrome, clindamycin (A) 761; pyrimethamine (A) 761; trimethoprim/sulfamethoxazole (A) 761; atovaquone (A) 765; azithromycin (A) 764; clarithromycin/pyrimethamine (A) 765; clindamycin (A) 761; dapsone/pyrimethamine (A) 762; pyrimethamine (A) 761; pyrimethamine/clindamycin (A) 763; pyrimethamine/sulfadiazine (A) 762; trimethoprim/sulfamethoxazole (A) 761; trimetrexate (A) 765; trimetrexate/leucovorin (A) 765
- Transplantation**, bone marrow, antifungal prophylaxis (A) 921, itraconazole serum concentrations (CR) 140; heart, cyclosporine, interactions, erythromycin, isoniazid, rifampin (CR) 127; cyclosporine, vancomycin pharmacokinetics (CR) 374, simvastatin (RR) 235; renal, methylprednisolone pharmacokinetics (RR) 120; solid organ, hyperlipidemia (A) 879; vitamin E with cyclosporine, improved cyclosporine absorption (A) 67
- Trazodone**, compared with venlafaxine, major depression (A) 391
- Trifluoperazine**, compared with sulpiride, schizophrenia (A) 154
- Triglycerides**, ascorbic acid (A) 1129
- Trimethoprim**, with sulfamethoxazole, dosage, kidney failure (L) 1300; hyperkalemia (A) 427, liver disorder (CR) 875, toxoplasmosis (A) 761
- Trimetrexate**, with leucovorin, toxoplasmosis (A) 765
- Trousseau's syndrome**, heparin, continuous subcutaneous infusion (CR) 710
- Tuberculosis**, resistance (A) 1037

U-Z

- Ulcers**, peptic, anti-infectives (A) 1035
- United States Pharmacopoeial Convention**, expansion (NC) 551; mission, vision statements, resolutions (O) 925
- Uridine**, diabetic peripheral neuropathy (A) 775
- Uvelitis**, rifabutin (A) 1149
- Vaccines**, pediatrics (A) 69
- Valproate**, status epilepticus (A) 1042

- Valproate sodium**, increased serum alkaline phosphatase (L) 539
- Valproic acid**, autism (A) 51; with phenytoin, predicting phenytoin concentrations (RR) 470
- Vancomycin**, pharmacokinetics, continuous venous hemodiafiltration (CR) 374; resistance, prevention (NC) 1187; with rifampin/gentamicin, methicillin-resistant *Staphylococcus aureus* osteomyelitis (CR) 694
- Vasopressors**, intravenous, proarrhythmic effects (A) 269
- Venlafaxine**, adverse reactions (A) 391; compared with imipramine, major depression (A) 391; compared with trazodone (A) 391; dosage (A) 392; pharmacokinetics (A) 388; pharmacology (A) 388; review (A) 387; toxicology (A) 388
- Verapamil**, compared with bisoprolol, angina (A) 411; extrapyramidal symptoms (A) 74; hyperprolactinemia (CR) 999
- Vigabatrin**, psychosis, child (CR) 1115
- Vincristine**, interaction, isoniazid (L) 201
- Vitamin C**, see **Ascorbic acid**
- Vitamin E**, coronary artery disease (A) 531; with cyclosporine, improved cyclosporine absorption (A) 67
- Vitamin K₁**, see **Phytonadione**
- Vlasses, Peter H**, Cardiovascular and Renal Drugs FDA Advisory Committee (NC) 960; nominated for appointment, public advisory committee, FDA (NC) 336
- Vomiting**, cyclic, sumatriptan (CR) 997
- Warfarin**, interaction, antiinflammatory drugs, nonsteroidal, (A) 1274 (E) 1289, aspirin (A) 1276, diflunisal (A) 1276, erythromycin (A) 908, etodolac (A) 1276, fenbufen (A) 1276, ibuprofen (A) 1276, indomethacin (A) 1276, ketoprofen (A) 1276, ketorolac (A) 1277, loroxicam (A) 1277, mefenamic acid (A) 1277, nabumetone (A) 1277, naproxen (A) 1277, nimesulide (A) 1277, phenylbutazone (A) 1277, sulindac (A) 1277, tenoxicam (A) 1277; reduction of activity, phytonadione (CR) 1228
- Wells, Barbara G**, chair-elect, Council of Faculties, American Association of Colleges of Pharmacy (NC) 552; dean, College of Pharmacy, Idaho State University (NC) 960; regent, American College of Clinical Pharmacy (NC) 336
- Wilson, Jac, uelny**, assistant professor (clinical), Department of Pharmacy Practice, Wayne State University (NC) 1321
- Women**, acquired immunodeficiency syndrome (NC) 451; arthritis, prevalence (NC) 810; cigarette smoking (NC) 110; maternal mortality, black vs. white (NC) 334; nicotine addiction (NC) 450; physical activity (NC) 450
- Zarowitz, Barbara J**, American College of Critical Care Medicine (NC) 814; Board Certified Nutritional Support Pharmacist (NC) 960; nominated for appointment, public advisory committee, FDA (NC) 336
- Zidovudine**, anemia, recombinant erythropoietin (A) 778; interaction, clarithromycin (A) 910; maternal transmission of HIV (A) 1287
- Zidovudine**, primary dependence (L) 540

AUTHOR INDEX

A-B

- Abate, Marie A** (coauthor) see **Baker, Daniel E**, 942
- Abter, Effathi LM** (coauthor) see **Tan, Winston W**, 246
- Ackerman, Bruce H** (coauthor) see **Olsen, Keith M**, 22
- Adams, Kirkwood F, Jr** (coauthor) see **Blase, Jamie S**, 396
- Adams, Stephen C** (coauthor) see **Laine, Gregory A**, 1110
- Adams, Val R** (author) Granisetron: The Second Serotonin-Receptor Antagonist (A) 1240; (coauthor) see **Holdsworth, Mark T**, 25
- Addis, Antonio** (author) Drug Use in Pregnancy and Lactation: the Work of a Regional Drug Information Center (L) 632
- Akaho, Eichi** (coauthor) see **Armstrong, Edward F**, 181
- Akinwande, Kayode I** (author) Dissolution of Phenytoin Precipitate with Sodium Bicarbonate in an Occluded Central Venous Access Device (CR) 707
- Alba, David** (coauthor) see **Torres, Enrique**, 1300; (coauthor) see **Zapatero-Hernandez, Pedro**, 199
- Albajar, Luis** (coauthor) see **Lopez-Herce, Jesus**, 632
- Alderman, Christopher P** (author) book review (B) 791; (author) Continuous Subcutaneous Heparin Infusion for Treatment of Trousseau's Syndrome (CR) 710; (coauthor) see **McClure, Anna F**, 938
- Alegret, Fabiola** (coauthor) see **Juarez Gimenez, Juan Carlos**, 317
- Alger, Sharon** (coauthor) see **Mehra, Ushma**, 935
- Allen, Elizabeth M** (author) Difference Between the Measured and Ordered Dose of Catecholamine Infusions (RR) 1095
- Althaus, Betsy L** (coauthor) see **Lam, Harriet H**, 921
- Ambrose, Paul G** (coauthor) see **Garvey, Michael J**, 872
- Amory, David W** (author) Macrolides Versus Azalides: A Drug Interaction Update (A) 906; (coauthor) see **Besette, Robert E**, 991
- Anand, Abhay** (author) Comment: Adjuvant Therapy Decisions in Node-Negative Breast Cancer (L) 940
- Anand, Ajay J** (coauthor) see **Anand, Abhay**, 940
- Anand, Namrata C** (coauthor) see **Anand, Abhay**, 940
- Anderson, Robert P** (author) Amphotericin B Toxicity Reduced by Administration in Fat Emulsion (CR) 496
- Archer, Scott R** (coauthor) see **Olsen, Keith M**, 246
- Armstrong, Edward F** (author) Japanese Pharmacy: Innovation Mixed with Tradition (A) 181
- Aron, David C** (coauthor) see **Dombrowski, Robert C**, 999
- Ashikari, Yuka** (coauthor) see **Karanari, Masee**, 83
- Aspinall, Sherrie, I.** (author) Recurrent Methicillin-Resistant *Staphylococcus aureus* Osteomyelitis: Combination Antibiotic Therapy with Evaluation by Serum Bactericidal Titers (CR) 694
- Atanasy, Halil** (author) Hypertension Associated with Ciprofloxacin Usage in an Infant (L) 1049
- Avila, Jose R** (author) Elevation of Hepatic Enzymes after Cata-nous Reactions Caused by Diltiazem (L) 317
- Ayestaran, Ana** (coauthor) see **Pascual-Arce, Begona**, 1197
- Beckmann, Kenneth A** (author) Is Something Broken that Requires Fixing? (A) 1156
- Badesha, Pritam S** (coauthor) see **Bhardwaj, Ashwani**, 1237
- Baena Diaz, Jose Miguel** (coauthor) see **Juarez Gimenez, Juan Carlos**, 317
- Baile, George R** (coauthor) see **Preston, Sandra L**, 1202
- Baker, Daniel E** (author) Authors' Reply: Selected Topics in Drug Information Access and Practice: An Update (L) 942
- Baldinger, Sandra L** (author) Nicotine Therapy in Patients with Alzheimer's Disease (A) 314
- Banakar, Umesh V** (coauthor) see **Bilger, Rhonda**, 946
- Banfield, Christopher R** (coauthor) see **Colucci, Robert D**, 939
- Bardy, Gust H** (coauthor) see **Wittkowsky, Ann K**, 1299
- Barjhoux, Claude E** (coauthor) see **Mallaret, Michel P**, 540
- Bartolomé, Patricia** (author) book review (B) 434
- Basmajian, Diana** (coauthor) see **Marra, Carlo A**, 1050
- Bates, Richard D** (author) Comment: Cost of rhDNase in Cystic Fibrosis (L) 1051
- Baxter, John D** (coauthor) see **Behbahani, Roya**, 760
- Becher, John A** (author) book review (B) 793
- Beckwith, Jan V** (coauthor) see **Gardner, Valerie Y**, 1161
- Bednarczyk, Edward M** (author) Establishment of a Drug Information Service on a Public-Access Computer Bulletin Board (RR) 1224
- Behbahani, Roya** (author) Hypersensitivity Reaction During Prolonged Use of Piperacillin/Tazobactam in Treatment of Osteomyelitis (L) 936; (author) Therapeutic Approaches for AIDS-Related Toxoplasmosis (A) 760
- Bejarano, Dolores** (coauthor) see **Avila, Jose R**, 317
- Belgado, Bernadette S** (author) Use of Zidovudine to Prevent Maternal Transmission of HIV (A) 1287
- Beil, Amber K** (author) Polyarthralgia Associated with Prazosin Use (L) 937
- Bellanger, Renee A** (coauthor) see **Crowther, Roger S**, 859
- Beltran Marques, Marian A** (coauthor) see **Canovas Martinez, Andres**, 1115
- Benson, John M** (author) Sumatriptan in the Treatment of Cyclic Vomiting (CR) 997
- Berg, Mary J** (coauthor) see **Lewis, Dale P**, 726
- Berry, Elliot M** (coauthor) see **Caraco, Joseph**, 843
- Bertch, Karen E** (coauthor) see **Mattos, Todd W**, 174
- Besette, Robert E** (author) Treatment of Non-HIV Cryptosporidial Diarrhea with Azithromycin (CR) 991
- Betageri, Gura V** (author) book review (B) 321
- Bhardwaj, Ashwani** (author) Isoniazide-Induced Nonconvulsive Status Epilepticus (CR) 1237
- Bhavani, Sujata M** (author) Monitoring of Intravenous Quinidine Infusion in the Treatment of *Plasmodium falciparum* Malaria (CR) 33
- Biery, John C** (author) Adenosine in Acute Theophylline Intoxication (A) 1285
- Bilger, Rhonda** (author) book review (B) 946
- Bingefors, Kerstin, A.J.** (author) Prescription Drug Use and Health Care Use Among Swedish Patients Treated with Antidepressants (RR) 566
- Bjornson, H Stephen** (coauthor) see **Sangha, Kiranpal S**, 117, 939
- Black, Peter N** (author) Probable Interaction Between Fluoxetine and Itraconazole (L) 1048
- Blashinsky, Paul C** (coauthor) see **Keating, Anne**, 538
- Blake, Kathryn V** (author) book review (B) 791
- Blancher, Amanda** (coauthor) see **Lopez, Alfonso**, 787
- Blatman, Brian** (coauthor) see **Bradley, Carole A**, 681
- Blazer, Dan G** (coauthor) see **Walstein, Sharon M**, 359
- Blivin, Jany L** (coauthor) see **Hebert, Mary E**, 260
- Blase, Jamie S** (author) Torsemide: A Pyridine-Sulfonamide Diuretic (A) 396
- Bonda, Luis** (coauthor) see **Espino, Francisco**, 1168
- Bonati, Maurizio** (coauthor) see **Addis, Antonio**, 632
- Bonet, Concepción** (coauthor) see **Lopez-Herce, Jesus**, 632
- Bonfigli, Mark F** (author) Thrombocytopenia in Intensive Care Patients: A Comprehensive Analysis of Risk Factors in 314 Patients (RR) 835
- Bonthuis, Nancy E** (coauthor) see **Van Dyke, Don C**, 1055
- Book, Linda S** (coauthor) see **Benson, John M**, 997
- Borden, E Keith** (coauthor) see **Willison, Donald J**, 1208
- Berzak, Steven** (coauthor) see **Tisdale, James E**, 269
- Boulton, David W** (coauthor) see **Fawcett, J Paul**, 987
- Bourdel-Marchasson, I** (coauthor) see **Pingaudon, G**, 634
- Boyce, Eric G** (author) Comment: Effect of Lithium in Water Handling (L) 1304
- Brace, Steven R** (coauthor) see **Jones, Ronald J**, 586

Bradley, Carole A (author) Quality Assessment of Economic Evaluations in Selected Pharmacy, Medical, and Health Economics Journals (RR) 681
 Brantley, Helen T (coauthor) see Ohri, Linda K, 1028
 Bricealand, Laurie L (author) Recent Advances: Antifungals (A) 1035; (coauthor) see Preston, Sandra L, 1202
 Briggs, Gerald G (author) book review (B) 1056
 Brown, Glen R (author) Erythromycin-Induced Hypotension (L) 934
 Brown, Murray G (coauthor) see Sketris, Ingrid S, 576
 Burnakis, Thomas G (author) Another Perspective on Monitoring Anticoagulation Therapy (E) 1045
 Burnett, David A (coauthor) see Yim, Josephine M, 475
 Bussey, Henry I (coauthor) see Haines, Stuart T, 892
 Busières, Jean-François (author) Application of International Consensus Meeting Criteria for Classifying Drug-Induced Liver Disorders (CR) 875

C-D

Calabrese, Joseph R (coauthor) see Fatemi, S.H., 1302
 Caley, Charles F (author) Sulpiride: An Antipsychotic with Selective Dopaminergic Antagonist Properties (A) 152
 Callist, Peter T (author) Peripheral Diabetic Neuropathy: Current Concepts in Treatment (A) 769
 Campana, Carlo (author) Efficacy and Pharmacokinetics of Simvastatin in Heart Transplant Recipients (RR) 235
 Canada, Andrew T (coauthor) see Jacobs, James E, 793
 Canaday, Bruce R (author) Propofol-Associated Bromide in the Management of Hyperhidrosis Associated with Spinal Cord Injury (CR) 489
 Canovas Martinez, Andres (author) Vigabatrin-Associated Reversible Aute Psychosis in a Child (CR) 1115
 Capers, Christi C (author) Optimal Gentamicin Dosing in Neonates (L) 430
 Caraco, Yoseph (author) Carbamazepine Pharmacokinetics in Obese and Lean Subjects (RR) 843
 Carcas, Antonio J (coauthor) see Recuenso, Isabel, 935
 Cardoni, Alex A (author) Risperidone: Review and Assessment of Its Role in the Treatment of Schizophrenia (A) 610
 Carleton, Bruce C (coauthor) see Marra, Carlo A, 1050
 Carlson, James A (coauthor) see Kaa, Kathleen A, 251
 Carney, Megan M (coauthor) see Ibrahim, Zafar Y, 200
 Carreras Soler, Maria Josep (coauthor) see Juarez Gimenez, Juan Carlos, 317
 Carriso, Carmen (author) Possible Vincristine-Isoniazid Interaction (L) 201
 Carson, William H (coauthor) see Markowitz, John S, 603
 Cassidy, L. Jane (author) Probable Ticlopidine-Induced Cholestatic Hepatitis (CR) 30
 Casso, Deborah E (coauthor) see Robinson, Dave, 539
 Ceyhan, Mehmet (coauthor) see Atasoy, Halil, 1049
 Chabursky, Boris (coauthor) see Bradley, Carole A, 681
 Chamberlain, Thomas M (coauthor) see Gonzalez, Edgar R, 671
 Chan, Elaine K (author) Pyrilium in Hypercholesterolemia (A) 625
 Chan, Thomas Y.K. (author) Adverse Interactions Between Warfarin and Nonsteroidal Antiinflammatory Drugs: Mechanisms, Clinical Significance, and Avoidance (A) 1274; (author) Beneficial Effects of Low-Dose Dopamine in Cirrhosis and Renal Insufficiency (L) 433; (author) Computer-Assisted Pharmacovigilance in Hospital Patients (L) 788; (author) Inadequate Warnings and Misleading Information in OTC Package Inserts for Medications Containing Methyl Salicylate (L) 1301; (author) Indapamide-Induced Severe Hyponatremia and Hypokalemia (CR) 1124; (author) Low-Dose Dopamine in Severe Right Heart Failure and Chronic Obstructive Pulmonary Disease (CR) 493; (author) Severe Asthma Attacks Precipitated by NSAIDs (L) 199
 Chandler, R. Frank (coauthor) see Sketris, Ingrid S, 576
 Chant, Clarence (author) Quinapristin/Dalfopristin (RP 59500): A New Streptogramin Antibiotic (A) 1022
 Chagnick, Edward K (coauthor) see Tan, Winston W, 22
 Chapron, Dennis J (coauthor) see Silverman, David A, 865
 Charland, Scott L (coauthor) see Stanek, Erik J, 425
 Chastler, A (coauthor) see Pinguano, G, 634
 Chavez, Cathy M (coauthor) see Holdsworth, Mark T, 16, 25
 Clark, Douglas A (coauthor) see Anderson, Robert P, 496
 Cleary, John D (coauthor) see Bricealand, Laurie L, 1035; (coauthor) see Tidwell, Bill H Jr, 1303
 Cole, Patricia L (coauthor) see Hagley, Michael T, 938
 Coley, Rebecca M.R. (author) book review (B) 436
 Collazo, Julio (coauthor) see Rodriguez, Jose, 138
 Collins, Dean S (coauthor) see Shaeffer, Mark S, 1088
 Collins, D. Michael (coauthor) see Hollie, Lisa M, 1042
 Colombo, Fabio (coauthor) see Addis, Antonio, 632
 Colucci, Robert D (author) Comment: Pharmacokinetic Variability of Aminoglycosides (L) 939
 Conesa, Dolores (author) Invasive Aspergillosis: A Life-Threatening Complication of Short-Term Steroid Treatment (CR) 1235
 Coadley, Eugene L (author) Bioelectrical Impedance Analysis as an Assessment of Diuresis in Congestive Heart Failure (RR) 1091

Cook, Marcus D (coauthor) see Marchiando, Rod J, 937
 Copeland, Paul M (author) Author's Reply: Therapeutic Failure with Levofloxacin Brand Interchange (L) 1050; (author) Two Cases of Therapeutic Failure Associated with Levofloxacin Brand Interchange (CR) 482
 Corboy, Dannielle L (author) Apomorphine for Motor Fluctuations and Freezing in Parkinson's Disease (A) 282
 Cornier, Pierre H (coauthor) see Mallaret, Michel P, 540
 Cory, Patrick R (author) Potential Use of Gabapentin and Lamotrigine (A) 1160
 Côté, Jean (coauthor) see Villeneuve, Jean-Pierre, 257
 Crimmon, Cara A (author) Misoprostol for Tinnitus (A) 782
 Cropp, Cheryl D (author) Ondansetron Use for Smoking Cessation (A) 1041
 Crowe, Helen M (coauthor) see Nicolas, David P, 994
 Crowell, Edward B (coauthor) see Higa, Gerald M, 134
 Crowther, Roger S (author) In Vitro Stability of Ranitidine Hydrochloride in Enteral Nutrient Formulas (RR) 859
 Cruz-Flores, Salvador (coauthor) see Malkoff, Marc D, 381
 Cuddy, Paul G (coauthor) see Mattox, Todd W, 174
 Cury, James D (coauthor) see Panley, Timothy R, 5
 Da Silva, Clêber DC (coauthor) see Addis, Antonio, 632
 Dager, William E (author) Adjusting Phenytoin Concentrations by the Scheiner-Tozer Method in Adults with Pronounced Hypoalbuminemia (RR) 667; (author) book review (B) 1305
 Daniel, Vincent C (coauthor) see Mallaret, Michel P, 540
 Daniel, Jacqueline R (author) Extrapyramidal Symptoms Associated with Calcium-Channel Blockers (A) 73
 Danish, Michele A (coauthor) see Generoni, Joyce A, 365
 Danziger, Larry H (coauthor) see Schoonover, Lori L, 501
 Dasta, Joseph F (coauthor) see Wolfe, Thomas A, 36
 Davidson, H. Edward (coauthor) see Gonzalez, Edgar R, 671
 Davies, Campbell (coauthor) see Villeneuve, Jean-Pierre, 257
 Davis, George A (coauthor) see Olsen, Keith M, 246
 Davis, Thomas D (coauthor) see Timm, Edward G, 240
 Dean, J. Michael (coauthor) see Allen, Elizabeth M, 1095
 Decamps, A (coauthor) see Pinguano, G, 634
 Del Corral, Maria Miguel (coauthor) see Avila, Jose R, 317
 Delgado Cordón, Fructoso (coauthor) see Canovas Martinez, Andres, 1115
 DiFazio, Louis T (coauthor) see Wagner, Beril K.J., 349
 DiGregorio, Victoria Yanovsky (author) Lorenzo's Oil Therapy of Adrenoleukodystrophy (A) 312
 Doering, Paul L (author) book review (B) 1053
 Dombrowski, Robert C (author) Verapamil-Induced Hyperprolactinemia Complicated by a Pituitary Incidentaloma (CR) 999
 Doyle, Ian C (coauthor) see Munar, Myrna Y, 374
 Draugalis, JoLaine R (coauthor) see Katz, Michael D, 1218
 Drusano, George L (coauthor) see Preston, Sandra L, 1202
 Duncan, Marilyn H (coauthor) see Holdsworth, Mark T, 16, 25
 Dupuis, Robert E (author) book review (B) 944; (coauthor) see Kirk, Julianne K, 879
 Durán Pou, Salvador (coauthor) see Juarez Gimenez, Juan Carlos, 317

E-G

Eccvit, Zafar (coauthor) see Atasoy, Halil, 1049
 Edén, Tony (coauthor) see Ohlsson, Lennart J, 972
 Edwards, Caroline (coauthor) see Urquhart, Robert, 787
 Edwards, David J (coauthor) see Slaughter, Richard L, 619
 Einarsson, Thomas J (coauthor) see Bradley, Carole A, 681; (coauthor) see Rovers, John P, 852
 Elholm, Charles M (coauthor) see Malikali, James, 698
 Emerson, J.P. (coauthor) see Pinguano, G, 634
 Enlund, K. Hannea (coauthor) see Wallenius, Sirpa H, 1213
 Epelde, Francisco (author) Angioedema Caused by Ranipril (L) 431; (author) Exfoliative Dermatitis Related to Omegra-zole (L) 82; (author) Leukocytoclastic Vasculitis and Hemoptysis After Treatment with Acedofenac (L) 1168
 Erdem, Gülüz (coauthor) see Atasoy, Halil, 1049
 Espada, Brian L (author) book review (B) 944
 Escrive Aparisi, Amelia (coauthor) see Canovas Martinez, Andres, 1115
 Espinosa, Enrique (coauthor) see Carriso, Carmen, 201; (coauthor) see Recuenso, Isabel, 935
 Estebalez, Antero (coauthor) see Pascual-Arce, Begona, 1197
 Ette, Ene I (author) book review (B) 946
 Etzel, Joseph V (author) book review (B) 1305
 Evans, R. Scott (author) book review (B) 202
 Exum, Barbara Jones (author) book review (B) 541
 Farris, Karen B (author) book review (B) 1055
 Fatemi, S.H. (author) Treatment of Valproate-Induced Alopecia (L) 1302
 Fawcett, J. Paul (author) Stability of Hydrocortisone Oral Suspensions Prepared from Tablets and Powder (RR) 967
 Ferreres, Joan Carles (coauthor) see Conesa, Dolores, 1235
 Fields, Scott (coauthor) see Hayn, Linh, 311
 Fine, Stanley R (author) Hydrochlorothiazide-Induced Acute Pulmonary Edema (CR) 701
 Fish, Douglas N (author) book review (B) 435
 Fjortoft, Nancy F (author) Comparison of Activities and Attitudes of Baccalaureate Level and Entry-Level Doctor of Pharmacy Graduates of the University of Illinois at Chicago (RR) 977
 Fletcher, Courtney V (coauthor) see Bricealand, Laurie L, 1035
 Foote, Edward F (coauthor) see Seysa, Carolyn, 187
 Force, Rex W (author) book review (B) 792; (author) Salivary Concentrations of Ketoconazole and Fluconazole: Implications for Drug Efficacy in Oropharyngeal and Esophageal Candidiasis (RR) 10
 Fox, Janet L (coauthor) see Xu, Quanyan A, 1106
 Frazee, Lawrence A (author) Ketoconazole to Prevent Acute Respiratory Distress Syndrome in Critically Ill Patients (A) 784; (author) Warfarin and Nonsteroidal Antiinflammatory Drugs: Why Not? (E) 1289
 Frazier, Jerry L (coauthor) see Young, Elizabeth G, 531
 Freeman, Collins D (coauthor) see Kim, Norma M, 186
 Friedland, David M (coauthor) see Asplund, Sherrie L, 694
 Fuchs, Henry J (coauthor) see Oster, Garry, 459
 Fujii, Masami (coauthor) see Armstrong, Edward P, 181
 Gabel, Kathryn A (coauthor) see Williamson, Donald J, 1208
 Gal, Peter (author) Recent Advances in Pediatrics (A) 66
 Gales, Barry J (author) Death Associated with Inappropriate Ketorolac Dosing (L) 1299; (author) Relationship Between the Administration of Selected Medications and Falls in Hospitalized Elderly Patients (RR) 354; (coauthor) see Gales, Mark A, 523
 Gales, Mark A (author) Rapid Infusion of Amphotericin B in Dextrose (A) 523; (coauthor) see Gales, Barry J, 1299
 Gallardo, Mariel (coauthor) see Rodriguez, Jose, 138
 Gamba, Fernando (author) Ciprofloxacin-Induced Hemochromatosis Purpura (L) 84
 Garcia, Agustín A (author) Isoniazid-Induced Fanconi Syndrome (CR) 590
 Garcia, Benito (coauthor) see Carriso, Carmen, 201; (coauthor) see Recuenso, Isabel, 935; (coauthor) see Torres, Enrique, 1300
 Gardner, Stephanie F (coauthor) see Granberry, Mark C, 1232
 Gardner, Valerie Y (author) Cisapride for the Treatment of Chronic Idiopathic Constipation (A) 1161
 Garnett, William R (coauthor) see Gidal, Barry E, 191
 Garrelis, James C (coauthor) see Mansour, Lisa I, 592
 Garvey, Michael J (author) Topical Fumagillin in the Treatment of Microsporidial Keratoconjunctivitis in AIDS (CR) 872
 Gaulin, Bruce D (coauthor) see Markowitz, John S, 789
 Gavazzi, Antonello (coauthor) see Campana, Carlo, 235
 Gayler, Melissa A (coauthor) see Yellon, Shannon L, 1010
 Generali, Joyce A (author) Knowledge of and Attitudes About Adverse Drug Reaction Reporting Among Rhode Island Pharmacists (CR) 365
 Gervais, Alan (author) Comment: Medications Unlabeled for Use in Children (L) 1052
 Giammetti, Vincent J (coauthor) see Poirier, Therese I, 78
 Gidal, Barry E (author) Perspective on Lamotrigine (E) 191; (author) Weight Gain and Gabapentin Therapy (L) 1048; (coauthor) see Cory, Patrick R, 1160; (coauthor) see Hollie, Lisa M, 1042
 Gilman, Jamie T (author) Author's Reply: Lamotrigine Dosing (L) 1173; (author) Autism and Associated Behavioral Disorders: Pharmacotherapeutic Intervention (A) 47; (author) Lamotrigine: An Antiepileptic Agent for the Treatment of Partial Seizures (A) 144
 Glimshalt, Boel AK (coauthor) see Ohlsson, Lennart J, 972
 Glue, Paul (coauthor) see Colucci, Robert D, 939
 Goldsmith, Charles H (coauthor) see Williamson, Donald J, 1208
 Gomez, Camilo R (coauthor) see Malkoff, Marc D, 381
 Gómez Matos, Jesus M (coauthor) see Gamba, Fernando, 84
 Gomez-Gra, Ernesto (coauthor) see Gamba, Fernando, 84
 Gonzalez, Edgar R (author) Disease-Based Assessment of Peripheral Vascular Disease in Nursing Facility Patients (RR) 671
 Gonzalez, Maria I (coauthor) see Avila, Jose R, 317
 Good, Michael I (coauthor) see Markowitz, John S, 789
 Gore-Harper, Mary Lea (coauthor) see Cropp, Cheryl D, 1041
 Godard, Michael P (author) book review (B) 320
 Granberry, Mark C (author) Exacerbation of Congestive Heart Failure After Administration of Polyethylene Glycol-Electrolyte Lavage Solution (CR) 1232
 Granello, Thoddes H, Jr (coauthor) see Timm, Edward G, 240
 Graves, Nina M (coauthor) see Kerrick, Jill M, 470
 Gregory, David F (coauthor) see Capers, Christi C, 430
 Grigg, Cedric F (author) Comment: Steroid Treatment of Mild Chronic Asthma (L) 1170
 Grunberger, George (coauthor) see Jaber, Linda A, 573
 Gums, John G (author) Recent Advances: Ambulatory Care and Family Medicine (A) 716
 Gurley, Bill J (coauthor) see Olsen, Keith M, 246
 Guven, Kadri (author) Hyperprolactinemia and Galactorrhea with Standard-Dose Farnotidine Therapy (L) 788

H-J

Habra, Magdi (coauthor) see Busières, Jean-François, 875
 Haddad, Stephen (coauthor) see Tan, Winston W, 22

Hagley, Michael T (author) Adenosine Use in a Pregnant Patient with Supraventricular Tachycardia (L) 938; (author) book review (B) 1053

Haines, Stuart T (author) Thrombosis and the Pharmacology of Antithrombotic Agents (A) 892

Hailey, Kathleen R (coauthor) see **Gidal, Barry E**, 1048

Hall, Philip D (author) Adjuvant Therapy of Node-Negative Breast Cancer (A) 289; (author) Authors' Reply: Adjuvant Therapy Decisions in Node-Negative Breast Cancer (L) 941

Hall, Rayna Kneuper (coauthor) see **Hall, Philip D**, 289, 941

Halperin, Lawrence S (coauthor) see **Cassidy, L. Jane**, 30

Halperin, Jerome A (author) Medicine, Pharmacy, and Industry—A Fly's Eye View of Health Care (O) 925

Hanson, Joseph T (coauthor) see **Wallsten, Sharon M**, 359

Hara, Dimitri S (coauthor) see **Skoutakis, Vasiliou A**, 1252

Haraden, Brennan (coauthor) see **Hagley, Michael T**, 938

Harrell, Colleen C (author) Oral Vitamin K: An Option to Reduce Warfarin's Activity (CR) 1228

Hartzema, Abraham G (coauthor) see **Wallenius, Sirpa H**, 1213

Hasselberger, Mary Beth (author) Efficacy of Mesna for Prevention of Hemorrhagic Cystitis After High-Dose Cyclophosphamide Therapy (A) 918

Hayball, Peter J (coauthor) see **McClure, Anna F**, 938

Healy, Daniel P (coauthor) see **Briceland, Laurie L**, 1035; (coauthor) see **Saunga, Kiranpal S**, 117, 939

Hebert, Mary E (author) Anaphylactoid Reactions with Intraperitoneal Cisplatin (CR) 260

Hendrickson, Joseph R (author) Pharmacoeconomic Benefit of Antibiotic Step-Down Therapy: Converting Patients from Intravenous Ceftriaxone to Oral Cefprozil Proxetil (RR) 561

Hernández, Jesús M (coauthor) see **Sacristán, Jose Antonio**, 719

Hernando, Gabriel (coauthor) see **Rodríguez, José**, 138

Herrero, Alicia (coauthor) see **Carrón, Carmen**, 201

Herruz, Cynthia C (coauthor) see **Capers, Christi C**, 430

Hewitt, Thomas J (coauthor) see **Pollak, P Timothy**, 486

Heyneman, Catherine A (author) Topical Nonsteroidal Antiinflammatory Drugs for Acute Soft Tissue Injuries (A) 780; (coauthor) see **Gardner, Valerie Y**, 1161

Hicks, Vern A (coauthor) see **Sketris, Ingrid S**, 576

Higa, Gerald M (author) Severe, Disabling Neurologic Toxicity Following Cisplatin Retreatment (CR) 134

Hilleman, Daniel E (coauthor) see **Lucas, B Daniel Jr**, 629

Hipple, Thomas F (coauthor) see **Nahata, Milap C**, 125

Hogan, Thanh T (coauthor) see **Belgado, Bernadette S**, 1287

Holdsworth, Mark T (author) Assessment of Chemotherapy-Induced Emesis and Evaluation of a Reduced-Dose Intravenous Ondansetron Regimen in Pediatric Outpatients with Leukemia (RR) 16; (author) book review (B) 86; (author) Continuous Midazolam Infusion for the Management of Morphine-Induced Myoclonus (CR) 25

Holle, Lisa M (author) Valproate Use in Status Epilepticus (A) 1042

Hosain, SM Hamid (coauthor) see **Laine, Gregory A**, 1110

Housel, Glenda J (coauthor) see **Malesker, Mark A**, 867

Howard, Patricia A (author) Amiodarone for the Maintenance of Sinus Rhythm in Patients with Atrial Fibrillation (A) 596; (author) Effect of Vitamin C on Plasma Lipids (A) 1129

Howe, Ted L (coauthor) see **Dager, William E**, 667

Hsu, Irene (author) Comparative Evaluation of the Safety and Efficacy of HMG-CoA Reductase Inhibitor Monotherapy in the Treatment of Primary Hypercholesterolemia (A) 743; (author) Hyperkalemia and High-Dose Trimethoprim-Sulfamethoxazole (A) 427

Hinbard, Eleanor J (coauthor) see **Sketris, Ingrid S**, 576

Hulicz, Darrell T (coauthor) see **Bonfiglio, Mark F**, 835

Huse, Daniel M (coauthor) see **Oster, Gerry**, 459

Huynh, Linh (author) Alprazolam for Tinnitus (A) 311

Iacoma, Isabella (coauthor) see **Campana, Carlo**, 235

Ibrahim, Zafar Y (author) Safe Use of Haloperidol in Acute Intermittent Porphyria (L) 200

Iersich, A Lane (coauthor) see **Rovers, John P**, 852

Impicciatore, Piero (coauthor) see **Addis, Antonio**, 632

Inciardi, John F (coauthor) see **Dager, William E**, 667

Ineson, Dag G.L. (coauthor) see **Bingefors, Kerstin A.L.**, 566

Isbedjian, Michael (coauthor) see **Bradley, Carole A**, 681

Jaber, Linda A (author) Diabetes and Related Metabolic Risk Factors Among Arab Americans (RR) 573; (coauthor) see **Calisti, Piero T**, 769

Jack, David Broadfoot (coauthor) see **Johnston, Brian**, 982

Jacobs, James R (author) book review (B) 793

Jacobs, Lori R (coauthor) see **Mauro, Vincent F**, 465

Jameson, John P (coauthor) see **Rider, Joan M**, 663

Jani, Bhavdeep R (coauthor) see **McPherson, Gail S**, 539

Jermann, Hubertus P.A. (coauthor) see **Alderman, Christopher P**, 710

Jewesson, Peter J (coauthor) see **Nicholls, Tessa A**, 1081

Jiang, Ruoying (coauthor) see **Fawcett, J Paul**, 987

Joe, Ronald H (coauthor) see **Skoutakis, Vasiliou A**, 1252

Johns, Melanie D (author) Acute Pulmonary Edema Associated with Oral Metoprolol Use (CR) 370

Johns, Thomas E (author) Bioprostol: Is This Just Another Beta-Blocker for Hypertension or Angina? (A) 403

Johnson, Nelda E (coauthor) see **Hsu, Irene**, 743

Johnston, Brian (author) Psychometric Profiling of the Elderly Using the Cambridge Cognitive Examination (RR) 982

Jones, Kristen M (author) book review (B) 1306

Jones, Ronald J (author) Probable Propafenone-Induced Transient Global Amnesia (CR) 586

Juarez Gimenez, Juan Carlos (author) Angioneurotic Edema Produced by Enalapril (L) 317

Jue, Sandra G (coauthor) see **Bell, Amber K**, 937; (coauthor) see **Marchiando, Rod J**, 937

Julia, Antoni (coauthor) see **Pascual-Arce, Begonia**, 1197

K-L

Kaa, Kathleen A (author) Emergency Department Resource Use by Patients with Migraine and Asthma in a Health Maintenance Organization (RR) 251

Kanra, Güler (coauthor) see **Atayso, Halli**, 1049

Kaplan, Barbara (author) Desogestrel, Norgestimate, and Gestodene: The Newer Progestins (A) 736; (coauthor) see **Wandstrat, Todd L**, 166

Karpink, Emilie L (coauthor) see **Timm, Edward G**, 240

Katz, Michael D (author) HIV Infection and AIDS: Attitudes and Knowledge of Arizona Pharmacists (RR) 1218

Kauffman, Matthew J (coauthor) see **Biery, John C**, 1285

Keating, Anne (author) Carbamazepine-Induced Stevens-Johnson Syndrome in a Child (L) 538

Keen, Diane M (coauthor) see **Akinwande, Kayode I**, 707

Kelstimur, Fahrettin (coauthor) see **Güven, Kadri**, 788

Kelly, H William (author) Aerosolized Beta₂-Agonists Do Not Induce Bronchial Hyperactivity in Healthy Adults (RR) 848

Kephart, George C (coauthor) see **Sketris, Ingrid S**, 576

Kerrick, Jill M (author) Predicting Unbound Phenytoin Concentrations in Patients Receiving Valproic Acid: A Comparison of Two Prediction Methods (RR) 470

Kessler, John (coauthor) see **Hebert, Mary E**, 260

Kier, Karen L (coauthor) see **Bonfiglio, Mark F**, 835

Kim, Harold L (author) Diclofenac-Associated Thrombocytopenia and Neutropenia (CR) 713

Kim, Norma M (author) Minocycline for Rheumatoid Arthritis (A) 186

Kintzel, Polly E (author) Low Itaconazole Serum Concentrations Following Administration of Itaconazole Suspension to Critically Ill Allogeneic Bone Marrow Transplant Recipients (CR) 140

Kirk, Julianne K (author) Approaches to the Treatment of Hyperlipidemia in the Solid Organ Transplant Recipient (A) 879

Kline, Sandra S (coauthor) see **Harrell, Colleen C**, 1228

Kodama, Yasuo (coauthor) see **Kuranari, Masae**, 83

Korhonen, Maarit J.H. (coauthor) see **Wallenius, Sirpa H**, 1213

Kostman, Jay R (coauthor) see **Behbahani, Roya**, 936

Kotzke, Theunis J van W (coauthor) see **Truter, Ilse**, 1302

Kovacs, Michael J (coauthor) see **Kim, Harold L**, 713

Kuehl, Angela K (author) Reimbursement Erythropoietin for Zidovudine-Induced Anemia in AIDS (A) 778

Kuranari, Masae (author) Effect of Phenytoin on Phenobarbital Pharmacokinetics in a Patient with Epilepsy (L) 83

Kyllönen, Kay S (coauthor) see **Bednarczyk, Edward M**, 1224

Lacey, Michael J (coauthor) see **Oster, Gerry**, 459

Lai, Rita P (coauthor) see **Katz, Michael D**, 1218

Laine, Gregory A (author) Polyethylene Glycol Nephrotoxicity Secondary to Prolonged High-Dose Intravenous Lorazepam (CR) 1110

Lam, Harriet H (author) Antifungal Prophylaxis in Bone Marrow Transplant (A) 921

Lancôt, Krista L (coauthor) see **Bradley, Carole A**, 681

Langley, Paul C (author) Comment: Substantiation in Pharmacoeconomic Evaluations (L) 942

Lauby, Vincent L (coauthor) see **Mallaret, Michel P**, 540

Lazowick, Andrea L (author) Potential Withdrawal Syndrome Associated with SSRI Discontinuation (A) 1284

Leasure, Mary M (coauthor) see **Holdsworth, Mark T**, 16

Lee, Mary W.L. (coauthor) see **Ejorff, Nancy F**, 977

Lesar, Timothy S (coauthor) see **Preston, Sandra L**, 1202

Lesh, Beth A (coauthor) see **Hall, Philip D**, 289

Leung, C.Y. (coauthor) see **Chan, Thomas Y.K.**, 1301

Levin, Gary M (author) book review (B) 1054, 1054; (coauthor) see **Lazowick, Andrea L**, 1284

Levine, Marc (coauthor) see **Marras, Carlo A**, 1050

Levine, Mitchell A.H. (coauthor) see **Willison, Donald J**, 1208

Levitt, Ralph (coauthor) see **Sylvester, Robert K**, 1118

Levy, Micha (coauthor) see **Caraco, Yonah**, 843

Lewis, Dale P (author) Phenytoin-Folic Acid Interaction (A) 726

Li Wan Po, Alain (coauthor) see **Johnston, Brian**, 982

Liberto, Rhonda B (coauthor) see **Gonzalez, Edgar R**, 671

Linares, Mariano (coauthor) see **Lopez, Alfonso**, 787

List, Alan F (coauthor) see **Kintzel, Polly E**, 140

Lobo, Bob L (author) book review (B) 203

Lodha, Ajay (coauthor) see **Fine, Stanley R**, 701

Lomestore, Ben M (author) Glutathione in Health and Disease: Pharmacotherapeutic Issues (A) 1263; (coauthor) see **Preston, Sandra L**, 1202

López, Alfonso (author) Autoimmune Hemolytic Anemia Induced by Diclofenac (L) 787

Lopez, Andres (coauthor) see **Pascual-Arce, Begonia**, 1197

Lopez, Larry M (coauthor) see **Johns, Thomas E**, 403

Lopez-Herce, Jesús (author) Benzyl Alcohol Poisoning Following Diazepam Intravenous Infusion (L) 632

Lonson, Isidore S (author) Hydroxyurea-Induced Fever: Case Report and Review of the Literature (CR) 132

M-N

Ma, Frank H (coauthor) see **Olsen, Keith M**, 246

MacArthur, Rodger D (coauthor) see **Mauro, Vincent F**, 465

MacKenzie, Susan L (coauthor) see **Pollak, P Timothy**, 486

MacLean, David R (coauthor) see **Sketris, Ingrid S**, 576

Magee, Michael J (coauthor) see **Pauky, Timothy R**, 5

Mahowald, James A (coauthor) see **Malesker, Mark A**, 867

Majcher, Claudine M (coauthor) see **Wagner, Bertl K.J.**, 349

Malesker, Mark A (author) Eosinophilia Associated with Bupropion (CR) 867

Mallekal, James (author) Gastrointestinal Complications Associated with Intramuscular Ketorolac Tromethamine Therapy in the Elderly (CR) 698

Malkoff, Marc D (author) Sinus Arrest after Administration of Intravenous Metoprolol (CR) 381

Mallaret, Michel P (author) Zepelol: Primary Dependence in an Unaddicted Patient (L) 540

Malone, Margaret (coauthor) see **Lomestore, Ben M**, 1263; (coauthor) see **Mehra, Ushma**, 935

Malone, Patrick M (coauthor) see **Malesker, Mark A**, 867

Maly, Melissa M (coauthor) see **Gidal, Barry E**, 1048

Manasco, Penelope K (author) Comment: Lamotrigine Dosing (L) 1173

Manciet, G (coauthor) see **Pinganaud, G**, 634

Mansur, Lisa I (author) Rebound of Plasma Free Phenytoin Concentration Following Plasmapheresis in a Patient with Thrombotic Thrombocytopenic Purpura (CR) 592

Marchiando, Rod J (author) Probable Terfenadine-Fluoxetine-Associated Cardiac Toxicity (L) 937

Mariscal, Dolores (coauthor) see **Conesa, Dolores**, 1235

Markowitz, John S (author) Interactions Between Antipsychotic and Antihypertensive Drugs (A) 603; (author) Significance of Plasma Thiothixene Concentrations (L) 789

Markowski, Susan J (author) Automatic Therapeutic Substitution: Cost Savings with Intravenous Push Fentanyl (L) 316

Marquardt, Kathy A (author) Fentanyl Remaining in a Transdermal System Following Three Days of Continuous Use (RR) 969

Marra, Carlo A (author) Cost of rhDNase in Cystic Fibrosis (L) 1050

Martin, Bradley R (coauthor) see **Bonfiglio, Mark F**, 835

Martineau, Pierre (author) Heparin Inhalation for Asthma (A) 71

Martinez, Cindy Lee (author) book review (B) 945

Mathews, Renia A (coauthor) see **Senoff, Michael G**, 690

Mattos, Todd W (author) Recent Advances: Parenteral Nutrition Support (A) 174

Matuschka, Paul R (author) Ceftriaxone-Theophylline Drug Interaction (CR) 378

Matusewicz, Karl A (coauthor) see **Yim, Josephine M**, 475

Matzner, Yacov (coauthor) see **Lonson, Isidore S**, 1302

Mauger, Theodore F (coauthor) see **Rider, Joan M**, 663

Mauro, Vincent F (author) Authors' Reply: Misadventures with Activated Charcoal (L) 85; (coauthor) see **Mauro, Vincent F**, 465

Mauro, Vincent F (author) Comparison of Tobramycin Pharmacokinetics After Administration by CRIS and a Traditional Intravenous Piggyback Infusion (RR) 465; (coauthor) see **Baldinger, Sandra L**, 314; (coauthor) see **Biery, John C**, 1285; (coauthor) see **Daniel, Jacqueline R**, 73; (coauthor) see **Mauro, Laurie S**, 85

McCart, Gary M (coauthor) see **Crimmon, Cara A**, 782

McClure, Anna F (author) Itaconazole Does Not Interfere with Fluorescence Polarization Immunoassay of Serum Digoxin (L) 938; (coauthor) see **Alderman, Christopher P**, 710

McCombs, Janet (author) book review (B) 203; (author) Update on Tocolytic Therapy (A) 515

McGeer, Patrick L (coauthor) see **Olsen, Keith M**, 246

McGuire, Timothy R (coauthor) see **Shaffer, Mark S**, 1088

McKerron, Ron (coauthor) see **Marra, Carlo A**, 1050

McPherson, Gail S (author) Isolated Increase in Serum Alkaline Phosphatase with Sodium Valproate Therapy (L) 539

Meagher, Bonnie C (coauthor) see **Kelly, H William**, 848

Menna, Andrés (coauthor) see **Lopez-Herce, Jesús**, 632

Mehra, Ushma (author) Cefazolin Use in Clinically Severe Obese Patients Undergoing Gastric Restrictive Surgery (L) 935

Mello, George P (coauthor) see **Staneh, Eric J**, 425

Menard, Susan M (coauthor) see **Gale, Barry J**, 354

Mendelson, Marilyn A (coauthor) see **Gonzalez, Edgar R**, 671

Meyer, Mary M (coauthor) see **Mann, Myrna Y**, 374

Neyers, David G (coauthor) see **Howard, Patricia A**, 1129

Niglio, Daniela (coauthor) see **Addis, Antonio**, 632

Miller, Elizabeth (coauthor) see **Bradley, Carole A**, 681

Miller, Lisa J (author) book review (B) 320

Mims, Garold O (coauthor) see **Mansur, Lisa I**, 592

Mirtallo, Jay M (coauthor) see *Mattex, Todd W*, 174
 Mittlemann, Nicole (coauthor) see *Bradley, Carole A*, 681
 Miyagawa, Clyde I (coauthor) see *Sangha, Kiranpal S*, 117, 939
 Molinaro, Joseph L (coauthor) see *Fine, Stanley R*, 701
 Montague, Luis Bouda (coauthor) see *Espide, Francisco*, 82, 431
 Montemartini, Carlo (coauthor) see *Campana, Carlo*, 235
 Monteiro-Romero, Jose B (coauthor) see *Pascual-Arce, Begona*, 1197
 Moreh, Jan S (coauthor) see *Trent, Kelley C*, 384
 Morono, Richard S (coauthor) see *Nabata, Milap C*, 125
 Morrison, Yvette Y (author) Hantavirus Pulmonary Syndrome: The Four Corners Disease (A) 57
 Morton, W Alexander (author) Venlafaxine: A Structurally Unique and Novel Antidepressant (A) 387
 Moshefeghi, Mervad (coauthor) see *Behbahani, Roya*, 760
 Muder, Robert R (coauthor) see *Aspinall, Sherrie L*, 694
 Munar, Myrna Y (author) Author's Reply: Cyclosporine and Vancomycin Disposition During Continuous Venovenous Hemodiafiltration (L) 941; (author) Cyclosporine and Vancomycin Disposition During Continuous Venovenous Hemodiafiltration (CR) 374
 Murphy, Shirley (coauthor) see *Kelly, H William*, 848
 Murray, Kim M (coauthor) see *Yelton, Shannon L*, 1010
 Murren, Richard W (coauthor) see *Mansur, Lisa I*, 592
 Musallam, Nabil A (coauthor) see *Marquardt, Kathy A*, 969
 Myers, Lesley (coauthor) see *Trent, Kelley C*, 384
 Myles, Geraldine L (coauthor) see *Malkoff, Marc D*, 381
 Nabata, Milap C (author) Stability of Cisapride in a Liquid Dosage Form at Two Temperatures (RR) 125; (coauthor) see *Bates, Richard D*, 1051; (coauthor) see *Force, Rex W*, 10; (coauthor) see *Gal, Peter*, 66; (coauthor) see *Paap, Christopher M*, 1300; (coauthor) see *Wintermeyer, Susan M*, 299
 Navarro, Olga (coauthor) see *Sacristan, Jose Antonio*, 719
 Nettig, Jeffrey A (coauthor) see *Fraze, Lawrence A*, 784
 Nemire, Ruth E (coauthor) see *Gidal, Barry E*, 1048
 Neutel, Joel M (coauthor) see *Coodley, Eugene L*, 1091
 Ng, David Y.F. (coauthor) see *Chan, Thomas Y.K.*, 1301
 Nguyen, Vu Xuan (author) Pharmacokinetics of a New Oral Course (L) 1169
 Nicholl, Tessa A (author) Amphotericin B Infusion-Related Toxicity: Comparison of Two- and Four-Hour Infusions (RR) 1181
 Nicolau, David P (author) Rifampin-Fluconazole Interaction in Critically Ill Patients (CR) 994
 Nightingale, Charles H (coauthor) see *Nicolau, David P*, 994
 Nimmo, Cindy J Resor (coauthor) see *Nicholl, Tessa A*, 1081
 Noormohamed, Saleem E (coauthor) see *Kuehl, Angela K*, 778
 North, Donald S (coauthor) see *Hendrickson, Joseph R*, 561
 Notman, Douglas D (coauthor) see *Rider, Joan M*, 663

O-R

O'Brien, Robin K (author) Gentamicin and Fludarabine Otolotoxicity (L) 200
 O'Connor, Nanette (coauthor) see *Pillans, Peter I*, 264
 O'Neill, Michael G (author) Felbamate-Induced Delayed Anaphylaxis (L) 430
 Occhipinti, Donna J (coauthor) see *Schoonover, Lori L*, 501
 Ogbonkiri, Justina E (author) book review (B) 321
 Ohlsson, Lennart J (author) Microbiological and Economic Evaluation of Multidose Infusion Pumps for Control of Cancer Pain (RR) 972
 Ohri, Linda K (author) US and Canadian Pharmacy Residencies and Fellowships: 1995 (A) 1028
 Okada, Fumihiko (author) Flaws in Multicenter, Placebo-Controlled Studies with Anxiolytics in Japan (L) 432
 Oken, Robert J (author) Pick's Disease: Possible New Directions in Prophylaxis and Therapy (L) 538
 Olsson, James R (coauthor) see *Hebert, Mary E*, 260
 Oliveras, Juan (coauthor) see *Pascual-Arce, Begona*, 1197
 Olsen, Alice F (coauthor) see *Allen, Elizabeth M*, 1095
 Olsen, Keith M (author) Comparison of Fluid Volumes with Whole Bowel Irrigation in a Simulated Overdose of Ibuprofen (RR) 266
 Olubadejo, Joseph O (author) book review (B) 87
 Omar, Sabiha J (coauthor) see *Robinson, Dave*, 539
 Ordovas Baines, Juan Pablo (coauthor) see *Canovas Martinez, Andres*, 1115
 Oster, Gerry (author) Effects of Recombinant Human DNase Therapy on Healthcare Use and Costs in Patients with Cystic Fibrosis (RR) 459
 Osterhaus, Jane T (coauthor) see *Kaa, Kathleen A*, 251
 Paap, Christopher M (author) Trimethoprim/Sulfamethoxazole Dosing During Renal Dysfunction (L) 1300
 Palocz, Frank P (author) book review (B) 541
 Parish, Roy C (author) book review (B) 945
 Pascual-Arce, Begona (author) Administration of Lipid Emulsion Versus Conventional Amphotericin B in Neutropenic Patients (RR) 1197
 Patel, Rakesh V (coauthor) see *Tisdale, James E*, 269
 Patel, Sundi (coauthor) see *O'Neill, Michael G*, 430
 Patterson, J Herbert (coauthor) see *Blone, Jamie S*, 396
 Pauley, Timothy R (author) Pharmacist-Managed, Physician-

Directed Asthma Management Program Reduces Emergency Department Visits (RR) 5
 Patoquin, Charles A (author) book review (B) 1054; (coauthor) see *Briceland, Laurie L*, 1035
 Perani, Guido (coauthor) see *Campana, Carlo*, 235
 Pestotnik, Stanley L (coauthor) see *Evans, R Scott*, 202
 Pettito, John M (author) book review (B) 1057
 Phan, Zung (coauthor) see *Reisner-Keller, Lori A*, 530
 Phillips, Joan (coauthor) see *Wandstrat, Todd L*, 318
 Phillips, Peter (coauthor) see *Nicholl, Tessa A*, 1081
 Piers, Luis (coauthor) see *Ruiz-Valverde, M Pilar*, 633
 Pierce, Dana Reid (coauthor) see *Thompson, Dennis F*, 189
 Pillans, Peter I (author) Tissue Necrosis and Necrotizing Fasciitis After Intramuscular Administration of Diclofenac (CR) 264
 Pincus, Kelly T (coauthor) see *Ohri, Linda K*, 1028
 Pinganaud, G (author) Cyproterone-Induced Hepatotoxicity (L) 634
 Poirier, Therese I (author) Clinical and Ethical Perspectives on Rationing of High-Cost Drugs (O) 78
 Pollak, P Timothy (author) Delirium Probably Induced by Clarithromycin in a Patient Receiving Fluoxetine (CR) 486
 Ponte, Charles D (coauthor) see *Cupp, Melanie Johns*, 370
 Ponzillo, John J (coauthor) see *Malkoff, Marc D*, 381
 Porco, Frank V (author) Pseudomonas aeruginosa as a Cause of Infectious Diarrhea Successfully Treated with Oral Ciprofloxacin (CR) 1122
 Poston, Sandra L (coauthor) see *Willison, Donald J*, 1208
 Preston, Sandra L (author) Dosing Adjustment of 10 Antimicrobials for Patients with Renal Impairment (RR) 1202; (coauthor) see *Bhavsani, Sujata M*, 33
 Probst, Lena (coauthor) see *O'Neill, Michael G*, 430
 Quintiliani, Richard (coauthor) see *Nicolau, David P*, 994
 Raddato, Vincenzo (coauthor) see *Campana, Carlo*, 235
 Radwanski, Elaine (coauthor) see *Calucci, Robert D*, 939
 Raich, Dennis W (coauthor) see *Holdsworth, Mark T*, 16
 Ramos, Jose (coauthor) see *Sacristan, Jose Antonio*, 719
 Rathbun, R Chris (coauthor) see *Morrison, Yvette Y*, 57
 Ratko, Thomas A (coauthor) see *Yim, Josephine M*, 475
 Rawson, Nigel S.B. (author) Impact of Preexisting Health Conditions on the Outcome of an Adverse Drug Reaction Alerting Program: Gastrointestinal Disorders Before Proxicam and Sulindac Therapy (RR) 676
 Recuenco, Isabel (author) Effect of Dexamethasone on the Decrease of Serum Phenytoin Concentrations (L) 935
 Reddy, Ramakota (coauthor) see *Wittkowski, Ann K*, 1299
 Reed, Kristine A (coauthor) see *Tornatore, Kathleen M*, 120
 Reed, Michael D (coauthor) see *Fraze, Lawrence A*, 1289; (coauthor) see *Gal, Peter*, 66
 Regan, Meredith M (coauthor) see *Oster, Gerry*, 459
 Regazzi, Mario B (coauthor) see *Campana, Carlo*, 235
 Reisner-Keller, Lori A (author) Oral Flumazenil in the Treatment of Epilepsy (A) 530
 Rello, Jordi (coauthor) see *Conesa, Dolores*, 1235
 Ribera, Ramon (coauthor) see *Ruiz-Valverde, M Pilar*, 633
 Richer, Monique (author) Fatal Hepatotoxicity Following Oral Administration of Amiodarone (CR) 582
 Rider, Joan M (author) Water Handling in Patients Receiving Haloperidol Decanoate (RR) 663
 Rihs, John D (coauthor) see *Aspinall, Sherrie L*, 694
 Rivera, Jose M (coauthor) see *Gambos, Fernando*, 84
 Robert, Sylvie (coauthor) see *Richer, Monique*, 582
 Roberts, David K (coauthor) see *Watson, William A*, 82
 Robinson, Dave (author) Possible Oral Lactate Exacerbation of Panic Disorder (L) 539
 Rodriguez, Jose (author) Angina Pectoris Following Cisplatin, Etoposide, and Bleomycin in a Patient with Advanced Testicular Cancer (CR) 138
 Rodvold, Keith A (coauthor) see *Schoonover, Lori L*, 501
 Rollins, Carol J (coauthor) see *Kintzel, Polly E*, 140
 Romeo, June H (coauthor) see *Dombrowski, Robert C*, 999
 Romero, Marilena (coauthor) see *Venturini, Francesca*, 1100
 Rosenbaum, Sara E (coauthor) see *Generali, Joyce A*, 365
 Ross, Joseph F (author) book review (B) 635
 Rossi, Stephen J (coauthor) see *Shaefer, Mark S*, 1088
 Rothstein, Jeffrey D (coauthor) see *Wetty, Devin F*, 1164
 Revers, John P (author) Meta-Analysis of Parenteral Clindamycin Dosing Regimens (RR) 852
 Ruiz-Valverde, Pilar (author) Ticlopidine-Induced Granulomatous Hepatitis (L) 633
 Rybak, Michael J (coauthor) see *Chant, Clarence*, 1022
 Rydberg, Tony S (coauthor) see *Ohlsson, Lennart J*, 972

S-T

Sacristan, Jose A (author) Use of Confidence Intervals and Sample Size Calculations in Health Economics Studies (A) 719
 Sage, Jacob I (coauthor) see *Corby, Danielle L*, 282
 Sakawa, Tetsumori (coauthor) see *Kuranari, Masae*, 83
 Sakata, Toshio (coauthor) see *Kuranari, Masae*, 83
 Sanchez, Higinio (coauthor) see *Lopez, Alfonso*, 787
 Sandmann, Beverly J (author) book review (B) 1307
 Sangha, Kiranpal S (author) Author's Reply: Pharmacokinetic Variability of Aminoglycosides (L) 939; (author) Pharmacokinetics of Once-Daily Dosing of Gentamicin in Surgical Intensive Care Unit Patients with Open Fractures (RR) 117

Santeiro, Maria L (coauthor) see *Markowsky, Susan J*, 316
 Sayers, Jeffrey F.B. (coauthor) see *Timm, Edward G*, 240
 Schaaf, Larry S (coauthor) see *Shaefer, Mark S*, 1088
 Scharman, Elizabeth J (author) book review (B) 542, 635
 Schein, Jeffrey R (author) Cigarette Smoking and Clinically Significant Drug Interactions (A) 1139
 Schielke, Gerald P (coauthor) see *Wetty, Devin F*, 1164
 Schoonover, Lori L (author) Piperacillin/Tazobactam: A New Beta-Lactam/Beta-Lactamase Inhibitor Combination (A) 501
 Schreiner-Daherty, Janet S (author) Tobramycin-Induced Hypersensitivity Reaction (CR) 704
 Schroeder, Donna J (coauthor) see *Baldinger, Sandra L*, 314; (coauthor) see *Chan, Elaine K*, 625; (coauthor) see *DiGregorio, Victoria Yanovsky*, 312
 Schuster, Brenda G (coauthor) see *Cassidy, L Jane*, 30
 Schwenk, Michael H (coauthor) see *Wang, Fei*, 1051
 Schwinghammer, Terry L (coauthor) see *Haseleberger, Mary Beth*, 918
 Scott, Gregory E (coauthor) see *Wagner, Bertil K.J.*, 349
 Scott, Noel (coauthor) see *Johnston, Brian*, 982
 Scott, Shane D (coauthor) see *Alderman, Christopher P*, 710
 Seaba, Hazel H (author) Comment: Selected Topics in Drug Information Access and Practice: An Update (L) 941
 Seay, Russell E Jr (author) Comment: Cyclosporine and Vancomycin Disposition During Continuous Venovenous Hemodiafiltration (L) 941
 Segal, Jack L (coauthor) see *Coodley, Eugene L*, 1091
 Segarra Medrano, Alfons (coauthor) see *Ruiz-Valverde, Pilar*, 633
 Seike, Masataka (coauthor) see *Kuranari, Masae*, 83
 Senef, Michael G (author) Use of Haloperidol Infusions to Control Delirium in Critically Ill Adults (CR) 690
 Seyns, Carolyn (author) Calcium-Channel Blockers for Prophylaxis of Radiocontrast-Associated Nephrotoxicity (A) 187
 Shaefer, Mark S (author) Evaluation of the Pharmacokinetic Interaction Between Cimetidine or Famotidine and Cyclosporine in Healthy Men (RR) 1088
 Shannahan, Allen F (author) Comment: Comparison of HMG-CoA Reductase Inhibitors (L) 1304
 Shepherd, John D (coauthor) see *Nicholl, Tessa A*, 1081
 Shindo, Kunitiko (author) Inhibitory Effect of Azelastine on Platelet Activating Factor-Like Activity in Eosinophils in Asthmatic Patients (L) 318
 Silverman, David A (author) Lymphopenic Effect of Carbamazepine in a Patient with Chronic Lymphocytic Leukemia (CR) 865
 Simko, Robert J (author) Activated Clotting Time Versus Activated Partial Thromboplastin Time for Therapeutic Monitoring of Heparin (A) 1015
 Simons, Carmine (coauthor) see *Bradley, Carole A*, 681
 Sketris, Ingrid S (author) Prescribing Patterns of Antiepileptic Drugs and Prevalence of Hypercholesterolemia in the Nova Scotia Population More Than 65 Years Old (RR) 576; (coauthor) see *Pollak, P Timothy*, 486
 Skoutnik, Vasilios A (author) Comparative Role of Omeprazole in the Treatment of Gastroesophageal Reflux Disease (A) 1252
 Slaughter, Richard L (author) Recent Advances: The Cytochrome P-450 Enzymes (A) 619; (coauthor) see *Jaber, Linda A*, 573
 Slawson, David C (coauthor) see *Shannahan, Allen F*, 1304
 Small, Ralph E (coauthor) see *Exum, Barbara Jones*, 541
 Smedley, Bjorn (coauthor) see *Blingsford, Kerstin A.L.*, 566
 Smith, David HG (coauthor) see *Coodley, Eugene L*, 1091
 Smith, Gary H (coauthor) see *Baker, Daniel E*, 942
 Solis, R Thomas (coauthor) see *Laine, Gregory A*, 1110
 Sonne, Susan C (coauthor) see *Morton, W Alexander*, 387
 Soori, Gamini S (coauthor) see *Malesker, Mark A*, 867
 Soper, John T (coauthor) see *Hebert, Mary E*, 260
 Sosa, Pilar (coauthor) see *Torres, Enrique*, 1300
 Spahn, Cynthia N (author) Effect of Clomethal on Athletic Performance (A) 75
 Sparling, Terence G (coauthor) see *O'Brien, Robin K*, 200
 Spilner, Sarah A (coauthor) see *Hsu, Irem*, 743
 Spotnitz, Alan J (coauthor) see *Wagner, Bertil K.J.*, 349
 Sramek, John J Jr (author) book review (B) 86, 86
 St. Pierre, Edith (coauthor) see *Bradley, Carole A*, 681
 Staneck, Eric J (author) Xanthine Interference with Digipramide-Thallium-201 Myocardial Imaging (A) 425; (coauthor) see *Simko, Robert J*, 1015
 Stanford, Richard H (coauthor) see *Canaday, Bruce R*, 489
 Stanon, Preston D (coauthor) see *Sylvester, Robert K*, 1118
 Stewart, Ronald B (author) The Future of Pharmacy: Armageddon or Pollyanna? (E) 1292
 Stratta, Robert J (coauthor) see *Shaefer, Mark S*, 1088
 Strauberg, Kathleen M (coauthor) see *Mattex, Todd W*, 174
 Stumbo, Phyllis J (coauthor) see *Lewis, Dale P*, 726
 Stampf, James L (author) book review (B) 1306
 Sullivan, Robert J, Jr (coauthor) see *Wallsten, Sharon M*, 359
 Sylvester, Robert K (author) Opioid-Induced Muscle Activity: Implications for Managing Chronic Pain (CR) 1118
 Szasz, Karen E.M. (coauthor) see *Crowther, Roger S*, 859
 Takeyama, Masaharu (coauthor) see *Kuranari, Masae*, 83
 Tan, Winston W (author) Paromomycin-Associated Pancreatitis in HIV-Related Cryptosporidiosis (CR) 22
 Tatsukawa, Hiroshi (coauthor) see *Kuranari, Masae*, 83
 Therratt, R Steven (coauthor) see *Marquardt, Kathy A*, 969
 Thompson, Dennis F (author) Local Analgesia with Opioid Drugs (A) 189

Thulin, Lars A (coauthor) see **Ohlsson, Lennart J**, 972
Tidwell, Bill H, Jr (author) Folinic Acid-Phenylalanine: A Drug-Drug Interaction? (L) 1303
Timm, Edward G (author) Adverse Drug Reaction Reporting in a Multicenter Surveillance Study (RR) 240
Tinklenberg, Jared R (coauthor) see **Robinson, Dave**, 539
Tisdale, James E (author) Proarrhythmic Effects of Intravenous Vasopressors (A) 269
Tognoni, Gianni (coauthor) see **Venturini, Francesca**, 1100
Toler, Steven M (author) Comment: Fluorescein as a Circulation Determinant (L) 1052
Tornatore, Kathleen M (author) Repeated Assessment of Methylprednisolone Pharmacokinetics During Chronic Immunosuppression in Renal Transplant Recipients (RR) 120
Torres, Enrique (author) No Interaction Between Dopamine and Phenytoin (L) 1300
Tracy, Timothy S (author) Stereochemistry in Pharmacotherapy: When Mirror Images Are Not Identical (A) 161
Trenger, Sheldou M (coauthor) see **Bonfiglio, Mark F**, 835
Trent, Kelley D (author) Multigland Failure Associated with Lomustine Overdose (CR) 384
Trisell, Lawrence A (coauthor) see **Xu, Quanyan A**, 1106
Troutman, William G (coauthor) see **Schretlen-Doherty, Janet S**, 704
Truter, Ilse (author) Prescribing of Analgesic Agents in a South African Patient Population (L) 1302
Tseng, Alice L (author) Rifabutin-Associated Uveitis (A) 1149
Tseng, Faye FW (coauthor) see **Simko, Robert J**, 1015
Tuchman, Roberto F (coauthor) see **Gilman, Jamie T**, 47
Tyrey, Mary J (coauthor) see **Wallsten, Sharon M**, 359

U-Z

Ukhun, Imelne A (author) Compatibility of Haloperidol and Diphenhydramine in a Hypodermic Syringe (L) 1168
Ulmer, Jack L (coauthor) see **Garvey, Michael J**, 872
Urquhart, Robert (author) Increased Theophylline Clearance During Hemofiltration (L) 787
Uy, Cherry C (coauthor) see **Zuckerman, Gary B**, 869
Vainio, Kirsti K (coauthor) see **Wallenius, Sirpa H**, 1213
Valles, Jordi (coauthor) see **Conesa, Dolores**, 1235
Valley, Amy W (coauthor) see **Adams, Val R**, 1240
Van Boerum, Don H (coauthor) see **Allen, Elizabeth M**, 1095
Van Dyke, Don C (author) book review (B) 1055; (coauthor) see **Lewis, Dale F**, 726
Vander Tuin, Elton L (coauthor) see **Jones, Ronald J**, 586
Vaughan, Leigh M (coauthor) see **Martinez, Pierre**, 71
Vaughan, Leslie J (coauthor) see **Holdsworth, Mark T**, 25
Vecina, Santiago Tomas (coauthor) see **Epele, Francisco**, 82, 431
Venturini, Francesca (author) Acute Myocardial Infarction Treatments in 58 Italian Hospitals: A Drug Utilization Survey (RR) 1100
Venuto, Rocco C (coauthor) see **Tornatore, Kathleen M**, 120
Verbeck, Stephen R (coauthor) see **Bonfiglio, Mark F**, 835
Verga, Michael A (coauthor) see **Morton, W Alexander**, 387
Vermeulen, Lee C, Jr (coauthor) see **Yim, Josephine M**, 475
Vignán, Mario (coauthor) see **Campana, Carlo**, 235
Villeneuve, Jean-Pierre (author) Suspected Ciprofloxacin-Induced Hepatotoxicity (CR) 257
Visconte, Ernest B (coauthor) see **Porco, Frank V**, 1122
Vissing, Richard S (coauthor) see **Matuschka, Paul R**, 378
Vlases, Peter H (coauthor) see **Yim, Josephine M**, 475
von Knorring, Lars (coauthor) see **Bingefors, Kerstin A.L.**, 566
Vondracek, Thomas G (author) Beta-Lactam Antibiotics: Is Continuous Infusion the Preferred Method of Administration? (A) 415
Wagner, Bertil K.J. (author) Effects of Intravenous Fentanyl on Gastric Acid Secretion in Patients Undergoing Cardiac Surgery (RR) 349
Wagner, Mary L (coauthor) see **Corbo, Dannielle L**, 282
Walawander, Cynthia A (coauthor) see **Timm, Edward G**, 240
Walker-Renard, Pamela (author) Pruritus Associated with Intravenous Rifampin (CR) 267
Wallenius, Sirpa H (author) Self-Initiated Modification of Hypertension Treatment in Response to Perceived Problems (RR) 1213
Wallsten, Sharon M (author) Medication Taking Behaviors in the High- and Low-Functioning Elderly: MacArthur Field Studies of Successful Aging (RR) 359
Walmley, Sharon L (coauthor) see **Tseng, Alice L**, 1149
Walsh, William (coauthor) see **Capers, Christi C**, 430
Wandstrat, Todd L (author) Pseudotumor Cerebri Responsive

to Acetazolamide (L) 318; (author) Use of Erythropoietin in Premature Neonates: Controversies and the Future (A) 166
Wang, Fei (author) Comment: Piperacillin/Tazobactam Dosing: A New Beta-Lactam/Beta-Lactamase Inhibitor Combination (L) 1051
Watling, Sharon M (author) Acute Respiratory Distress Syndrome (A) 1002
Watson, Bernadene (coauthor) see **Capers, Christi C**, 430
Watson, William A (author) Clinical Interpretation of Urine Cocaine and Metabolites in Emergency Department Patients (L) 82; (author) Comment: Misadventures with Activated Charcoal (L) 84
Webb, Charles R (coauthor) see **Tisdale, James E**, 269
Weber, Stanley S (coauthor) see **Caley, Charles F**, 152
Wedworth, Shawn M (author) Dietary Flavonoids in Atherosclerosis Prevention (A) 627
Wehrli, Agathe (author) book review (B) 435
Welge, Lynda S (coauthor) see **Timm, Edward G**, 240
Wells, Barbara G (coauthor) see **Markowitz, John S**, 603
Welty, Devin F (author) Potential Treatment of Amyotrophic Lateral Sclerosis with Gabapentin: A Hypothesis (O) 1164
Wertheimer, Albert I (author) book review (B) 202
Westlund, Ronald (coauthor) see **Wallsten, Sharon M**, 359
Whipple, Julianne K (author) book review (B) 944
White, Donald B (coauthor) see **Mauro, Vincent F**, 465
White, Laura M (coauthor) see **Granberry, Mark C**, 1232
Whitney, Harvey AK, Jr (author) Influencing the Destiny of Pharmacy (E) 1297
Willhite, Laurie A (coauthor) see **Lewis, Dale F**, 726
Willson, Donald J (author) Experience in the Development of a Postmarketing Surveillance Network: The Pharmacy Medication Monitoring Program (RR) 1208
Wilson, Bryan D (coauthor) see **Watson, William A**, 82
Winter, Michael E (coauthor) see **Spann, Cynthia N**, 75
Wintermeyer, Susan M (author) Rimantadine: A Clinical Perspective (A) 299
Wise, Tamara C (coauthor) see **Higa, Gerald M**, 134
Wittkowsky, Ann K (author) Oral Mucosal Ulceration from Disopyramide (L) 1299
Wolfe, Thomas A (author) Use of Nitric Oxide Synthase Inhibitors as a Novel Treatment for Septic Shock (A) 36
Wolff, Denise L (coauthor) see **Kerrick, Jill M**, 470
Wolfson, Bernard B (author) Comment: Therapeutic Failure with Levofloxacin Brand Interchange (L) 1049
Wong, Bruce (coauthor) see **Willson, Donald J**, 1208
Woods, David J (coauthor) see **Fawcett, J Paul**, 987
Wordell, Cindy J (coauthor) see **Hsu, Irene**, 427
Xu, Quanyan A (author) Compatibility of Ondansetron Hydrochloride with Meperidine Hydrochloride for Combined Administration (RR) 1106
Yanos, John (coauthor) see **Watling, Sharon M**, 1002
Yee, Walter J (coauthor) see **Kintzel, Polly E**, 140
Yelton, Shannon L (author) The Role of Continuous Infusion Loop Diuretics (A) 1010
Yim, Josephine M (author) Surveillance of Colony-Stimulating Factor Use in US Academic Health Centers (RR) 475
Young, Elizabeth G (author) Vitamin E and the Risk of Coronary Artery Disease (A) 531
Yu, Victor L (coauthor) see **Aspinall, Sherrie L**, 694
Zafon, Carles (coauthor) see **Ruiz-Valverde, M Pilar**, 633
Zapater, Pedro (author) Acidosis and Extreme Hyperkalemia Associated with Cholestyramine and Spironolactone (L) 199
Zarowitz, Barbara J (coauthor) see **Tisdale, James E**, 269
Zimbalist, Elliot H (coauthor) see **Tan, Winston W**, 22
Zonerach, Samuel (coauthor) see **Fine, Stanley R**, 701
Zorn, Sherri L (coauthor) see **Benson, John M**, 997
Zuckerman, Gary B (author) Shock, Metabolic Acidosis, and Coma Following Ibuprofen Overdose in a Child (CR) 869
Zylber-Katz, Ester (author) Correction: Multiple Drug Interactions with Cyclosporine in a Heart Transplant Patient (L) 790; (author) Multiple Drug Interactions with Cyclosporine in a Heart Transplant Patient (CR) 127; (coauthor) see **Caraco, Joseph**, 843

962; Pharmacy Technician Education & Training, 1995 Directory, 815; *The Annals of Pharmacotherapy*, bound volumes, 198, 448, 464, 826, *PharmACE*, 96, 208, 324, 444, 546, 646, 800, 953, 1058, 1308, subscription, 112, 116, 228, 438, 547, 560, 658, 834, 966, 1076, 1192, subscription, gift, 1171; Therapeutics in the Elderly, 217, 806, 1062, 1079, 1193; books, journals, and reprints for pharmacy and pharmacotherapy, 90, 205, 223, 338, 534, 642, 796, 948, 1065, 1178, 1315; combination subscriptions, 215, 449, 652, 659

Lederle Laboratories, Ziac, ifc-Jan, ifc-Mar, ifc-May, ifc-J/A, ifc-Oct, ifc-Dec; Zosyn, ifc-Feb, 233, ifc-Apr, 457, ifc-Jun, 661, ifc-Sep, 967, ifc-Nov, 1195

Personnel Placement, California University of California, 809; Colorado Kaiser Permanente of Colorado, 1064; Connecticut University of Connecticut, 108; Florida University of Florida, 447; Georgia Mercer University, 1064; Louisiana Department of Veterans Affairs, 109, 214, 330, 445, 549, 649, 808; Massachusetts Northeastern University, 213; Michigan Wayne State University, 108, 446, 1313; Minnesota Diversified Pharmaceutical Services, 548; Montana University of Montana, 213; New Jersey Rutgers—The State University of New Jersey, 446, 809, 957; New York, Bassett Healthcare, 1313, State University of New York at Buffalo, 216; North Carolina, University of North Carolina, 213; Ohio Good Samaritan Hospital, 648, Harvey Whitney Books, 329, 447, 548, The Toledo Hospital, 809; Pennsylvania Janet Weiss Children's Hospital, 957, Scientific Connections, 329; Rhode Island University of Rhode Island, 329; South Carolina, Medical University of South Carolina, 1313

Pratt Pharmaceuticals, Procardia XL, ifc-Feb, ifc-Apr, ifc-Jun, ifc-Sep, ifc-Nov

Wyeth-Ayerst Laboratories, Cardene I.V., 193, 229, 345, 637, 863, 1137

INDEX ABBREVIATIONS

A: Article
 CR: Case Reports
 E: Editorial
 ifc: inside back cover
 ifc: inside front cover
 L: Letters
 NC: News and Comments
 O: An Opinion
 RR: Research Report

Statement of ownership, management, and monthly circulation (12 issues, \$120 annually) of *The Annals of Pharmacotherapy*, publication no. 1060-0280. Owner, Harvey Whitney Books Company. Publisher, editor, and managing editor, Harvey AK Whitney Jr. Headquarters of publisher, owner, and publication: 8044 Montgomery Road, PO Box 42696, Cincinnati, OH 45242. Known bondholders, mortgages, and other security holders: none. Average no. of copies of each issue from August 94 to September 95 and no. of copies of September 95: A. total no. copies printed (net press run) 7781, 7300; B. paid circulation (1) single copy sales (0); (2) mail subscription 5421, 5236; C. total paid circulation 5421, 5236; D. free distribution 374, 381; G. total distribution (C + F) 5795, 5617; H. office use, left over, etc. 1986, 1683; I. total (G + H) 7781, 7300. No. of issues published: 12. Date of filing: 27 September 1995. Signed: Harvey AK Whitney Jr, Publisher.

ADVERTISER INDEX

American College of Clinical Pharmacy PSAP, 220, 331
 Bayer Pharmaceuticals, Cipro, ifc-Jan, ifc-Mar, ifc-May, ifc-J/A, 1072, 1332
 Canadian College of Clinical Pharmacy 647
 Facts and Comparisons, 77, 332, 344, 1078
 Ferring Laboratories, Desmopressin, 965, 1077
 Harvey Whitney Books, CA/CTF, 1047; Children's Medications: A Parent's Guide, 1080, 1194; METS, 97, 197, 322, 553, 653, 827, 958, 1071; Pediatric Drug Formulations, 795,

